UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

 

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended DecemberMarch 31, 20172022

[   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

WELLNESS CENTER USA, INC.

(Name of small business issuer in its charter)

NEVADA

nevada

333-173216

27-2980395

(State or other jurisdiction of


incorporation or organization)

Commission
File Number

(IRS Employee


Identification No.)

2500 West Higgins Road, Ste. 780, Hoffman Estates, IL, 60169145 E. University Boulevard, Tucson, AZ85705

(Address of Principal Executive Offices)

(847) (847) 925-1885

(Issuer Telephone number)

Not Applicable

(Former name or former address, if changed since last report)

2500 West Higgins Road, Ste. 780, Hoffman Estates, IL, 60169

 

Copies of communication to:

Ronald P. Duplack, Esq.

Rieck and Crotty, P.C.

55 West Monroe Street, Suite 3625, Chicago, IL 60603

Telephone (312) 726-4646 Fax (312) 726-0647

Securities registered under Section 12(b) of the Exchange Act:

Title of each class registered:

Name of each exchange on which registered:

None

None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, par value $0.001


(Title of class)

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [   ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [   ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company filer. See definition of “accelerated filer” and “large accelerated filer” in Rule 12b-2 of the Exchange Act (Check one):

Large Accelerated Filer

Accelerated Filer

[   ]

[   ]

Non-Accelerated Filer

Smaller Reporting Company

[   ]

[X]

Emerging growth Company

1


Indicate by check mark whether the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.

Yes [   ] No [X]

The number of shares issued and outstanding of each of the issuer’s classes of common equity as of DecemberMarch 31, 20172022 was 91,329,202.126,377,077.


2


FORM 10-Q

WELLNESS CENTER USA, INC.

DECEMBERMARCH 31, 20172022

TABLE OF CONTENTS

PART I-- FINANCIAL INFORMATION

PART I— FINANCIAL INFORMATION

Item 1.

Condensed Consolidated Financial Statements

4

3

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

Item 3

Quantitative and Qualitative Disclosures About Market Risk

23

25

Item 4.

Control and Procedures

23

25

PART II--II— OTHER INFORMATION

Item 1

Legal Proceedings

26

Item 1A

1

Risk Factors

Legal Proceedings

26

Item 1A

Risk Factors26
Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

26

27

Item 3.

Defaults Upon Senior Securities

26

27

Item 4.

Mine Safety Disclosures.

26

27

Item 5.

Other Information

26

27

Item 6.

Exhibits

26

27

SIGNATURES

SIGNATURE

28


3


Wellness Center USA, Inc.

Condensed Consolidated Balance Sheets

 

 

 

 

 

 

 

December 31,

2017

 

September 30,

2017

 

 

 

 

 

(Unaudited)

 

 

ASSETS

 

 

 

 

Current Assets

 

 

 

 

Cash

$

23,594

$

29,369

Accounts receivable

 

5,000

 

24,999

Inventories

 

12,112

 

12,335

Prepaid expenses and other current assets

 

2,396

 

1,751

Total Current Assets

 

43,102

 

68,454

 

 

 

 

 

Property and equipment, net

 

4,112

 

5,126

Other assets

 

16,760

 

16,760

Total Other Assets

 

20,872

 

21,886

 

 

 

 

 

TOTAL ASSETS

$

63,974

$

90,340

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS' DEFICIT

 

 

 

 

Current Liabilities

 

 

 

 

Accounts payable and accrued expenses

$

314,926

$

203,367

Accrued payroll - officers

 

43,807

 

13,440

Deferred revenue

 

52,348

 

55,098

Convertible note payable

 

119,930

 

49,884

Loans payable from shareholders

 

89,500

 

59,000

Total Current Liabilities

 

620,511

 

380,789

 

 

 

 

 

Shareholders' Deficit

 

 

 

 

Common stock, par value $0.001, 185,000,000 shares authorized;

 

 

 

 

91,329,202 and 90,284,916 shares issued and outstanding, respectively

 

91,329

 

90,285

Additional paid-in capital

 

19,200,081

 

19,069,211

Accumulated deficit

 

(19,484,590)

 

(19,132,557)

Total Wellness Center USA shareholders' equity (deficit)

 

(193,180)

 

26,939

 

 

 

 

 

Non-controlling interest

 

(363,357)

 

(317,388)

Total Shareholder's deficit

 

(556,537)

 

(290,449)

 

 

 

 

 

TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT

$

63,974

$

90,340

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.


4


Wellness Center USA, Inc.

Consolidated Statements of Operations

 

 

 

 

 

 

 

Three Months Ended

December 31,

 

 

 

 

2017

 

2016

 

 

(Unaudited)

Sales:

 

 

 

 

Trade

$

15,500

$

89,000

Consulting services

 

11,000

 

14,125

Total Sales

 

26,500

 

103,125

 

 

 

 

 

Cost of goods sold

 

16,992

 

60,500

 

 

 

 

 

Gross profit

 

9,508

 

42,625

 

 

 

 

 

Operating expenses

 

334,163

 

416,563

 

 

 

 

 

Loss from operations

 

(324,655)

 

(373,938)

 

 

 

 

 

Other expenses

 

 

 

 

Amortization of debt discount

 

(70,047)

 

-

Interest expense

 

(3,300)

 

-

Total other expenses

 

(73,347)

 

-

 

 

 

 

 

LOSS FROM CONTINUING OPERATIONS

 

(398,002)

 

(373,938)

 

 

 

 

 

DISCONTINUED OPERATIONS

 

 

 

 

Loss from discontinued operations

 

-

 

(41,562)

 

 

 

 

 

NET LOSS

 

(398,002)

 

(415,500)

 

 

 

 

 

Net loss attributable to non-controlling interest

 

45,969

 

6,528

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO WELLNESS CENTER USA, INC.

$

(352,033)

$

(408,972)

 

 

 

 

 

BASIC AND DILUTED LOSS PER SHARE

 

 

 

 

Loss per share from continuing operations

$

(0.00)

$

(0.00)

Income (loss) per share from discontinued operations

$

(0.00)

$

(0.00)

Net loss per share

$

(0.00)

$

(0.01)

 

 

 

 

 

WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING

 

 

 

 

BASIC AND DILUTED

 

90,336,112

 

80,998,306

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.


5


Wellness Center USA, Inc.

Condensed Consolidated Statement of Shareholders' Deficit (Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common Stock

 

Additional

 

Accumulated

 

Total WCUI

 

Non-

controlling

 

 

 

Shares

 

Amount

 

Paid-in Capital

 

Deficit

 

Deficit

 

Interest

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance,

September 30,

2017

90,284,916

$

90,285

$

19,069,211

$

(19,132,557)

$

26,939

$

(317,388)

$

(290,449)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of stock

warrants

924,286

 

924

 

109,990

 

-

 

110,914

 

-

 

110,914

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair value of

common stock

issued for

services

120,000

 

120

 

20,880

 

-

 

21,000

 

-

 

21,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss for the

three months

ended December 31,

2017

-

 

-

 

-

 

(352,033)

 

(352,033)

 

(45,969)

 

(398,002)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31,

2017 (unaudited)

91,329,202

$

91,329

$

19,200,081

$

(19,484,590)

$

(193,180)

$

(363,357)

$

(556,537)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.


6


Wellness Center USA, Inc.

Condensed Consolidated Statements of Cash Flows

 

 

 

 

 

 

 

Three Months Ended

 

 

December 31,

 

 

2017

 

2016

 

 

(Unaudited)

Cash Flows from Operating Activities

 

 

 

 

Net loss

$

(398,002)

$

(415,500)

 

 

 

 

 

Adjustments to reconcile net loss to net cash used in operating

 

 

 

 

activities of continuing operations

 

 

 

 

Loss from discontinued operations

 

-

 

41,562

Depreciation expense

 

1,014

 

2,701

Amortization of debt discount

 

70,046

 

-

Fair value of common shares issued for services

 

21,000

 

38,150

Changes in Assets and Liabilities

 

 

 

 

(Increase) Decrease in:

 

 

 

 

Accounts receivable

 

19,999

 

(14,000)

Inventories

 

223

 

39,994

Prepaid expenses and other current assets

 

(645)

 

24,479

(Decrease) Increase in:

 

 

 

 

Accounts payable and accrued expenses

 

111,559

 

27,066

Accrued payroll taxes

 

-

 

12,204

Accrued payroll - officers

 

30,367

 

17,953

Deferred revenue

 

(2,750)

 

(5,701)

Net cash used in operating activities from continuing operations

 

(147,189)

 

(231,092)

Net cash used in operating activities from discontinued operations

 

-

 

(11,887)

Net cash used in operating activities

 

(147,189)

 

(242,979)

 

 

 

 

 

Cash Flows from Investing Activities

 

 

 

 

Purchases of property and equipment

 

-

 

(546)

Net cash used in investing activities from continuing operations

 

-

 

(546)

Net cash used in investing activities from discontinued operations

 

-

 

(1,704)

Net cash used in investing activities

 

-

 

(2,250)

 

 

 

 

 

Cash Flows from Financing Activities

 

 

 

 

Proceeds from loans payable

 

30,500

 

-

Exercise of stock warrants

 

110,914

 

-

Proceeds from common stock issuable

 

-

 

309,000

Net cash provided by financing activities

 

141,414

 

309,000

 

 

 

 

 

Net increase (decrease) in cash

 

(5,775)

 

63,771

 

 

 

 

 

Cash beginning of period

 

29,369

 

81,479

Cash end of period

$

23,594

$

145,250

 

 

 

 

 

Supplemental cash flows disclosures:

 

 

 

 

Interest paid

$

-

$

-

Taxes paid

$

-

$

-

 

 

 

 

 

Supplemental non-cash financing disclosures:

 

 

 

 

Non-controlling interest's share in losses of a subsidiary

$

45,969

$

6,528

2

 

Wellness Center USA, Inc.

Condensed Consolidated Balance Sheets

  March 31,  September 30, 
  2022  2021 
  (Unaudited)    
ASSETS        
Current Assets        
Cash $64,478  $32,079 
Accounts receivable  956   - 
Inventories, net  27,157   50,000 
Total Current Assets  92,591   82,079 
         
TOTAL ASSETS $92,591  $82,079 
         
LIABILITIES AND SHAREHOLDERS’ DEFICIT        
Current Liabilities        
Accounts payable and accrued expenses $662,395  $624,337 
Payroll taxes payable, past due  66,834   75,834 
Lease abandonment liability  547,878   672,878 
Loans payable from officers and shareholders, including $1,816,250 past due at March 31, 2022 - net of debt discount of $7,072 and $15,822, respectively  2,230,128   2,055,378 
Total Current Liabilities  3,507,235   3,428,427 
         
U.S. SBA loan payable  304,600   - 
Total Liabilities  3,811,835   3,428,427 
         
Shareholders’ Deficit        
Common stock, par value $0.001, 200,000,000 shares authorized; 126,377,077 and 123,877,077 shares issued and outstanding, respectively  126,377   123,877 
Additional paid-in capital  25,343,005   25,258,005 
Accumulated deficit  (28,699,761)  (28,389,628)
Total Wellness Center USA shareholders’ deficit  (3,230,379)  (3,007,746)
         
Non-controlling interest  (488,865)  (338,602)
Total Shareholder’s deficit  (3,719,244)  (3,346,348)
         
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT $92,591  $82,079 

The accompanying notes are an integral part of these condensed consolidated financial statements.


7


3

Wellness Center USA, Inc.

Condensed Consolidated Statements of Operations

  2022  2021  2022  2021 
  Three Months Ended  Six Months Ended 
  March 31,  March 31, 
  2022  2021  2022  2021 
  (Unaudited)  (Unaudited) 
             
Trade sales $99,990  $51,650  $264,542  $142,149 
                 
Cost of goods sold  10,400   58,950   36,400   139,050 
                 
Gross profit (loss)  89,590   (7,300)  228,142   3,099 
                 
Operating expenses  310,702   362,218   598,451   670,759 
                 
Loss from operations  (221,112)  (369,518)  (370,309)  (667,660)
                 
Other income (expenses):                
Interest expense  (44,664)  (31,993)  (86,251)  (58,151)
Amortization of debt discount  (4,375)  -   (8,750)  - 
Gain on settlement of debt  4,914   -   4,914   - 
Total other expenses, net  (44,125)  (31,993)  (90,087)  (58,151)
                 
NET LOSS  (265,237)  (401,511)  (460,396)  (725,811)
                 
Net loss attributable to non-controlling interest  87,317   188,334   150,263   331,936 
                 
NET LOSS ATTRIBUTABLE TO WELLNESS CENTER USA, INC.  (177,920)  (213,177)  (310,133)  (393,875)
                 
BASIC AND DILUTED LOSS PER SHARE $(0.00) $(0.00) $(0.00) $(0.01)
                 
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING                
BASIC AND DILUTED  125,752,077   120,333,327   125,127,077   119,639,577 

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

Wellness Center USA, Inc.

Condensed Consolidated Statements of Shareholders’ Deficit (Unaudited)

  Shares  Amount  Capital  Deficit  Deficit  Interest  Total 
  Common Stock  Additional
Paid-in
  Accumulated  Total WCUI  Non-
controlling
    
  Shares  Amount  Capital  Deficit  Deficit  Interest  Total 
                      
Balance, December 31, 2021 (unaudited)  125,127,077  $125,127  $25,300,505  $(28,521,841) $(3,096,209) $(401,548) $(3,497,757)
                             
Fair value of common stock issued for services to officers and directors  1,250,000   1,250   42,500   -   43,750   -   43,750 
                             
Net loss for the three months ended March 31, 2022  -   -   -   (177,920)  (177,920)  (87,317)  (265,237)
                             
Balance, March 31, 2022 (unaudited)  126,377,077  $126,377  $25,343,005  $(28,699,761) $(3,230,379) $(488,865) $(3,719,244)
                             
Balance, September 30, 2021  123,877,077  $123,877  $25,258,005  $(28,389,628) $(3,007,746) $(338,602) $(3,346,348)
                             
Fair value of common stock issued for services to officers and directors  2,500,000   2,500   85,000   -   87,500   -   87,500 
                             
Net loss for the six months ended March 31, 2022  -   -   -   (310,133)  (310,133)  (150,263)  (460,396)
                             
Balance, March 31, 2022 (unaudited)  126,377,077  $126,377  $25,343,005  $(28,699,761) $(3,230,379) $(488,865) $(3,719,244)
                             
Balance, December 31, 2020 (unaudited)  119,639,577  $119,639  $25,104,736  $(27,764,061) $(2,539,686) $38,348  $(2,501,338)
                             
Fair value of vested stock options  -   -   10,882   -   10,882   -   10,882 
                             
Fair value of common stock issued for services to officers and directors  1,387,500   1,388   40,237   -   41,625   -   41,625 
                             
Net loss for the three months ended March 31, 2021  -   -   -   (213,177)  (213,177)  (188,334)  (401,511)
                             
Balance, March 31, 2021 (unaudited)  121,027,077  $121,027  $25,155,855  $(27,977,238) $(2,700,356) $(149,986) $(2,850,342)
                             
Balance, September 30, 2020  118,252,077  $118,252  $25,053,616  $(27,583,363) $(2,411,495) $181,950  $(2,229,545)
                             
Fair value of vested stock options  -   -   21,764   -   21,764   -   21,764 
                             
Fair value of common stock issued for services to officers and directors  2,775,000   2,775   80,475   -   83,250   -   83,250 
                             
Net loss for the six months ended March 31, 2021  -   -   -   (393,875)  (393,875)  (331,936)  (725,811)
                             
Balance, March 31, 2021 (unaudited)  121,027,077  $121,027  $25,155,855  $(27,977,238) $(2,700,356) $(149,986) $(2,850,342)

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

Wellness Center USA, Inc.

Condensed Consolidated Statements of Cash Flows

  2022  2021 
  Six Months Ended 
  March 31, 
  2022  2021 
  (Unaudited) 
Cash Flows from Operating Activities        
Net loss $(460,396) $(725,811)
         
Adjustments to reconcile net loss to net cash used in operating activities:        
Amortization of right-of-use asset  -   6,961 
Amortization of debt discount  8,750   - 
Provision for excess and slow moving inventories  -   100,000 
Fair value of common shares issued for services  87,500   83,250 
Fair value of stock options issued for services  -   21,764 
Gain on settlement of debt  (4,914)  - 
Changes in Assets and Liabilities        
(Increase) Decrease in:        
 Accounts receivable  (956)  (9,018)
 Inventories  22,843   (137,933)
 Prepaid expenses and other assets  -   500 
(Decrease) Increase in:        
 Accounts payable and accrued expenses  42,972   109,567 
 Payroll taxes payable  (9,000)  (7,500)
 Lease abandonment liability  (125,000)  - 
 Lease liability  -   (6,961)
Net cash used in operating activities  (438,201)  (565,181)
         
Cash Flows from Financing Activities        
Proceeds from loans payable from officers and shareholders  326,000   660,000 
Repayments of loans payable from officers and shareholders  (160,000)  - 
Proceeds from SBA loan payable  304,600   - 
Net cash provided by financing activities  470,600   660,000 
         
Net increase in cash  32,399   94,819 
         
Cash beginning of period  32,079   51,320 
Cash end of period $64,478  $146,139 
         
Supplemental cash flows disclosures:        
Interest paid $-  $- 
Taxes paid $-  $- 

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

WELLNESS CENTER USA, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

FOR THE THREESIX MONTHS ENDED DECEMBERMARCH 31, 2017 AND 20162022 and 2021

NOTE 1 – BASIS OF PRESENTATION

Organization and Operations

Wellness Center USA, Inc. ("WCUI"(“WCUI” or the “Company”) was incorporated in June 2010 under the laws of the State of Nevada. The Company initially engaged in online sports and nutrition supplements marketing and distribution. The Company subsequently expanded into additional businesses within the healthcare and medical sectors through acquisitions, including Psoria-Shield Inc. (“PSI”), National Pain Centers, Inc. (“NPC”), and StealthCo Inc. (“SCI”), d/b/a Stealth Mark, Inc. On August 11, 2017, the Company entered into an agreement to sell 100% of the issued and outstanding shares of NPC, which has been accounted for as a discontinued operation on the condensed consolidated statement of operations for the three months ended December 31, 2016. See Note 3 for details relating to the sale.

The Company currently operates in the following business segments: (i) distribution of targeted Ultra Violet ("UV"Ultraviolet (“UV”) phototherapy devices for dermatology;dermatology and sanitation purposes; and (ii) authentication and encryption products and services. The segments are operated, respectively, through PSI and SCI.

Basis of Presentation of Unaudited Financial Information

The accompanying unaudited condensed consolidated financial statements of Wellness Center USA, Inc. and Subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the threesix months ended DecemberMarch 31, 20172022 are not necessarily indicative of the results that may be expected for the year ending September 30, 2018.2022.

COVID-19 Considerations

During the six months ended March 31, 2022, the COVID-19 pandemic did not have a material net impact on our operating results. In the future, the pandemic may cause reduced demand for our products if, for example, the pandemic results in a recessionary economic environment which negatively effects the customers who purchase our products.

Our ability to operate without significant negative operational impact from the COVID-19 pandemic will in part depend on our ability to protect our employees and our supply chain. The Company has endeavored to follow the recommended actions of government and health authorities to protect our employees. Since the onset of the COVID-19 pandemic, we maintained the consistency of our operations. However, the uncertainty resulting from the pandemic could result in an unforeseen disruption to our workforce and supply chain (for example an inability of a key supplier or transportation supplier to source and transport materials) that could negatively impact our operations.

Through March 31, 2022, the COVID-19 pandemic has not negatively impacted the Company’s liquidity position as of such date. Through March 31, 2022, the Company continues to generate cash flows through financing activities to meet its short-term liquidity needs, and it expects to maintain access to those shareholder loans. The Company has not observed any material impairments of its assets or a significant change in the fair value of its assets due to the COVID-19 pandemic.

Going Concern

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying condensed consolidated financial statements, the Company has not yet generated significant revenues and has incurred recurring net losses. During the threesix months ended DecemberMarch 31, 2017,2022, the Company incurred a net loss from continuing operations of $398,002$460,396 and used cash in operations from continuing operations of $147,189,$438,201, and had a shareholders’ deficit of $556,537$3,719,244 as of DecemberMarch 31, 2017.2022. In addition, loans payable of $1,816,250 and payroll taxes of $66,834 are past due. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

7

 

In addition, the Company's independent registered public accounting firm, in its report on the Company's September 30, 2017 financial statements, has raised substantial doubt about the Company's ability to continue as a going concern.

At DecemberMarch 31, 2017,2022, the Company had cash on hand in the amount of $23,594.$64,478. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and raising additional capital soon to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, we have funded our operations primarily through equity and debt financings and we expect to continue to rely on these sources of capital in the future. During the threesix months ended DecemberMarch 31, 2017,2022, the Company received $141,114$326,000 through debt financingshort-term loans from officers and the exercise of stock warrants.shareholders and $304,600 through a U.S. SBA loan payable.

No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stock holders,stockholders, in case of equity financing.


8


NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Consolidation

The Company'sconsolidated financial statements include the Company’s subsidiaries and the accounts of its subsidiaries for which it was determined that Company has operational and management control. The Company’s consolidated subsidiaries and/or controlled entities are as follows:

SCHEDULE OF COMPANY'S CONSOLIDATED SUBSIDIARIES

Name of consolidated
subsidiary or entity

State or other jurisdiction of incorporation or organization

Date of incorporation or formation

(date (date of
acquisition/disposition, if applicable)

Attributable interest

at
March 31, 2022

Psoria-Shield Inc. (“PSI”)

The State of Florida

June 17, 2009

(August 24, (August 2012)

100%

51%

StealthCo, Inc. (“StealthCo”)

The State of Illinois

March 18, 2014

100%

100%

Psoria Development Company LLC.Protec Scientific, Inc (“PDC”Protec”)

The State of Illinois

New York

January 15, 2015

50%

April 2020
32%

 

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence andreserves, accruals for potential liabilities, valuations of stock-based compensation, calculations,and realization of deferred tax assets, among others. Actual results could differ from these estimates.

Income (Loss) Per Share

Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the threesix months ended DecemberMarch 31, 20172022 and 2016,2021, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At DecemberMarch 31, 20172022 and 2016,2021, the dilutive impact of outstanding stock options of 6,822,0004,427,738 and 5,785,00012,602,738 shares, respectively, and outstanding warrants for 62,716,019and 64,208,15828,256,797 and 54,379,758 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive.

Revenue Recognition

The company records revenue under the guidance of Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (Topic 606) which requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services.

8

 

Revenue Recognition

TheFor trade sales, the Company recognizesgenerates its revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered to the customer, (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured. In addition to the aforementioned general policy, the following are the specific revenue recognition policies for each major category of revenue:

(i)Sale of products: The Company derives its revenues from sales contracts with customers with revenues being generated upon the shipment of merchandise. Persuasive evidence of an arrangement is demonstrated via sales invoicemerchandise, or contract; product delivery is evidenced by warehouse shipping log as well as a signed bill of lading from the vessel or rail company and title transfers upon shipment, based on free on board (“FOB”) warehouse terms; the sales price to the customer is fixed upon acceptance of the signed purchase order or contract and there is no separate sales rebate, discount, or volume incentive. When the Company recognizesfor consulting services, revenue no provisions are made for returns because, historically, there have been very few sales returns and adjustments that have impacted the ultimate collection of revenues. 

(ii)Consulting services: Revenue is recognized in the period services are rendered and earned under service arrangements with clients whereclients.

The Company sells its products through two main sales channels: 1) directly to customers who use its products (the “Direct Channel”) and 2) to distribution partners who resell its products (the “Indirect Channel”).

Under the Direct Channel, the Company sells its products to and receives payment directly from customers who purchase its products. Under the Indirect Channel, the Company has entered into distribution agreements that allow the distributors to sell its products and fulfill performance obligations under the agreements. During the six months ended March 31, 2022 and 2021, all of the Company’s products were sold through its Direct Channel.

We determine revenue recognition through the following steps:

Identification of the contract, or contracts, with a customer
Identification of the performance obligations in the contract
Determination of the transaction price
Allocation of the transaction price to the performance obligations in the contract
Recognition of revenue when, or as, we satisfy a performance obligation.

Revenue is generally recognized upon shipment or when a service fees are fixed or determinable and collectabilityhas been completed, unless we have significant performance obligations for services still to be completed. We recognize revenue when a material reversal is reasonably assured. 

no longer probable. Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. DeferredThere was 0 deferred revenue at DecemberMarch 31, 20172022 and 2016 was $52,348 and $55,098, respectively.


9


NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)September 30, 2021.

Non-controlling InterestInventories

Non-controlling interest representsInventories are stated at the non-controlling interest holder’s proportionate sharelower of cost or net realizable value. Cost is computed on a first-in, first-out basis. At March 31, 2022, primarily all of the equityinventories consisted of raw materials or work-in-progress. The Company provides inventory reserves based on excess and obsolete inventories determined primarily by future demand forecasts. The write down amount, if any, is measured as the difference between the cost of the Company’s majority-owned subsidiary, PDC. Non-controlling interestinventory and net realizable value based upon assumptions about future demand and charged to the provision for inventory, which is adjusted fora component of cost of sales. At the non-controlling interest holder’s proportionate sharepoint of the earningsloss recognition, a new, lower cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or lossesincrease in that newly established cost basis. At March 31, 2022 and other comprehensive income (loss), if any,September 30, 2021, the Company recorded a reserve of $173,930for excess and the non-controlling interest continues to be attributed its share of losses even if that attribution results in a deficit non-controlling interest balance.slow moving inventories.

Stock-Based Compensation

The Company periodically issues stock-based compensation to officers, directors, and consultants for services rendered, and as part of financing transactions. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors, employees, and for acquiring goods and services from non-employees, which include grants of stock options, and warrants to employees and non-employeesare recognized in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option and stock warrant grants to employeesthe financial statements based on their fair values in accordance with Topic 718. Stock option grants, which are generally time vested, will be measured at the authoritative guidance provided by the Financial Accounting Standards Board where thegrant date fair value of the award is measuredand charged to operations on the date of grant and recognizeda straight-line basis over the vesting period. The Company accountsRecognition of compensation expense for stock option and stock warrant grants to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option or warrant grants are immediately vested and the total stock-based compensation charge is recorded in the same period ofand manner as if the measurement date.Company has paid cash for the services.

The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods.

9

 

Recently Issued Accounting Pronouncements

In May 2014,June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from ContractsInstruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with Customers. ASU 2014-09 is a comprehensive revenue recognition standard thatan “expected loss” model, under which companies will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenueallowances based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costsexpected rather than incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein.losses. Entities will be able to transition toapply the standard either retrospectively orstandard’s provisions as a cumulative-effect adjustment to retained earnings as of the datebeginning of adoption.the first reporting period in which the guidance is effective. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company’s financial statements and disclosures.

In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02standard is effective for all interim and annual reporting periods beginning after October 1, 2023. The adoption of ASU 2016-13 is not expected to have a material impact on the Company’s financial position, results of operations, and cash flows.

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. ASU 2021-04 provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. An issuer measures the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange. ASU 2021-04 introduces a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2018.2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early adoption is permitted. A modified retrospective transition approach is requiredpermitted for lessees for capital and operating leases existing at, or entered into after,all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available.fiscal year that includes that interim period. The Company is in the process of evaluating the impactadoption of ASU 2016-022021-04 is not expected to have a material impact on the Company’s financial statements andor disclosures.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.


10


NOTE 3 – DISCONTINUED OPERATIONSLOANS PAYABLE FROM OFFICERS AND SHAREHOLDERS

On August 11, 2017,As of September 30, 2021, loans payable to officers and shareholders of $2,071,200 were outstanding and $1,165,250 was past due. During the six months ended March 31, 2022, the Company and its subsidiary, PSI, borrowed $326,000 from its officers and shareholders and repaid $160,000 of those loans. The loans have an interest rate of eight percent per annum and are due one year from the date of issuance. As of March 31, 2022, loans payable to officers and shareholders of $2,237,200 were outstanding and $1,816,250 was past due.

During the year ended September 30, 2021, in connection with a loan in the amount of $25,000, the Company awarded the lender 350,000 shares of its common stock, valued at $17,500 on the date of grant. The Company recorded the fair value of the shares as a discount to the debt, which will be amortized over the life of the loan. During the year ended September 30, 2021, the Company amortized $1,678 of the debt discount and the balance of the unamortized discount at September 30, 2021 was $15,822. During the three and six months ended March 31, 2022, the Company amortized $4,375 and $8,750, respectively, of the debt discount and the balance of the unamortized discount at March 31, 2022 was $7,072.

NOTE 4 – U.S. SMALL BUSINESS ADMINISTRATION LOAN PAYABLE

During the six months ended March 31, 2022, the Company entered into ana loan agreement with Dr. Jay Joshi to sell 100%the U.S. Small Business Administration (SBA) under which the Company borrowed $304,600. The note accrues interest at 3.75% per annum and calls for monthly payments of $1,569 beginning in February 2024, and maturing in February 2052. The loan is secured by all of the issued and outstanding shares of NPC Inc. (“NPC”) to Dr. Joshi. As part of the agreement, Dr. Joshi and NPC released the Company from any and all liabilities, claims and obligationsassets of the Company and is personally guaranteed by the Company’s Chief Executive Officer. The balance of $304,600 was due as of March 31, 2022.

10

NOTE 5 – LEASE LIABILITIES

Lease settlement liability

The Company leased its corporate office facility in Hoffman Estates, Illinois pursuant to a non-cancellable lease initiated in July 2016 and expiring February 28, 2024. The lease terms require a monthly payment of approximately $11,000. The Company vacated the facility in April 2020, in favor of Dr. Joshiits present facilities in Tucson AZ, which are provided by a shareholder on a rent-free basis. At the date of vacation, the Company had a remaining lease obligation of $631,587.

On or NPCabout June 29, 2020, the Company received notice that Hanover Hoffman Estates, LLC (“HHE”), filed case number 2020L006092 in the Circuit Court of Cook County alleging a failure to pay Base Rent and arisingabandonment of certain office space in Hoffman Estates, Illinois subject to a Commercial Lease dated May 26, 2016 (the “HHE Litigation”). HHE sought at least $672,878 in base rent and other amounts under the lease, as well as treble damages from or relating to the operation of the NPC business. Also as part of the agreement, Dr. Joshi’s employment agreement with NPC was terminatedCompany’s ex-CEO and all assets and liabilities of NPCtwo past Directors who were transferred to Dr. Joshiserving on our Board as of the date of the agreement, including $365,459lease. As of accrued compensation and shareholder advances owed to Dr. Joshi by NPC. TheMarch 31, 2022, the Company agreed to sell NPC to Dr. Joshi so that it could focus on its other business segments, PSI and Stealth Mark, which are technology companies, while NPC was a service business. Further,has recorded the eliminationfull amount of the underlined NPC liabilitiesjudgement due.

On October 6, 2021, HHE and the Company settled the HHE Litigation pursuant to Dr. Joshian agreement providing, among other things, that the Company agree to the entry of a final judgment order on the complaint in the amount of $725,795, which includes $657,194 in base rent awarded HHE by the Court on HHE’s Motion for Summary Judgment and the additional fees claimed by HHE and costs. HHE will significantly improve Wellness Center Inc.’s financial position. As partforebear on the enforcement of the agreement,judgment and will provide the Company agreed to issue Dr. Joshi stock options to purchase 500,000 shares of its common stock with an exercise price of $0.25 per share. Dr. Joshi continued to serve on the Company’s board of directors until February 5, 2018. During the year ended September 30, 2017, the Company recorded a $252,508 gain relating to this transaction.

Componentssatisfaction of the statement of operations relating to NPC forjudgment upon the three months ended December 31, 2016 were as follows:

Total Sales

$

37,402

 

 

 

Operating expenses

 

78,964

 

 

 

Loss from discontinued operations

$

(41,562)

NOTE 4 – LOANS PAYABLE FROM SHAREHOLDERS

Loans payable of $59,000 at September 30, 2017 consist of two unsecured note agreements issued in 2014 totaling to $9,000, and two short-term unsecured loans issued in fiscal 2017 totaling to $50,000. The loans have no stated interest rate and are due on demand. During the three months ended December 31, 2017, the Company borrowed $30,500 under three short-term unsecured loans. The loans have no stated interest rate and are due on demand. As of December 31, 2017, loans payable of $89,500 were outstanding.

NOTE 5 – CONVERTIBLE NOTE AGREEMENT

 

 

December 31,

 

September 30,

 

 

2017

 

2017

 

 

 

 

 

Convertible note payable

$

165,000

$

165,000

Debt discount – unamortized balance

 

(45,070)

 

(115,116)

Convertible note payable, net

$

119,930

$

49,884

In July 2017, the Company entered into a Convertible Note Payable Agreement with an individual under which the Company borrowed $165,000. Net proceeds receivedpayment by the Company underof $350,000, plus interest on the agreement were $150,000. In connection withprincipal amount thereof outstanding from time to time at the agreement,rate of 5% per annum (the “Settlement Amount”), until the Settlement Amount is paid in full.

An initial payment of $125,000 was due January 1, 2022. The Company received a letter of default from HHE on January 20, 2022, which provided the Company issued30 days to make the individual 165,000 restricted shares of its common stock and warrants to purchase 330,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.50 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company’s common stock at the fixed conversion price of $0.25 per share. The note matures in February 2018, but may be extended at the optionpayment or HHE could seek collection of the individual.Agreed Final Judgement Amount of $725,795. The Company may prepaymade the note at any time immediately followingpayment of $125,000 on February 10, 2022. The balance of $225,000 will be paid over a five-year period beginning on January 1, 2023, as follows: January 1, 2023 – $15,000 plus accrued interest only; January 1, 2024 – $15,000 plus accrued interest only; January 1, 2025 – $45,000 plus accrued interest; January 1, 2026 – $75,000 plus accrued interest; and January 1, 2027 – $75,000 plus accrued interest.

As of September 30, 2021, the issue date upon seven days’ prior written notice.

OnCompany had recorded a lease settlement liability of $672,878. During the datesix months ended March 31, 2022, the Company made a payment of $125,000 towards the agreement,Settlement Amount and as of March 31, 2022, the closing priceCompany has recorded a lease settlement liability of the common stock was $0.31 per share. As the conversion price embedded in the note agreement was below the trading price of the common stock on the date of issuance, a beneficial conversion feature (BCF) was recognized at the date of issuance.$547,878. The Company recognized a debt discount at the date of issuance in the aggregate amount of $150,000 related to the relative fair value of the warrants and beneficial conversion features, which comprised $94,704 related to the intrinsic value of beneficial conversion features and $55,296 related to the relative fair value of the warrants. The aggregate fair value of the warrants of $87,582 was based on a probability effected Black-Scholes option pricing model with a stock price of $0.31, volatility of 139.98% and risk-free rate of 1.28%. The unamortizedwill adjust any remaining balance of the debt discount at September 30, 2017 was $115,116. Duringliability after it has completed the three months ended December 31, 2017,payment and satisfaction of the Company amortized $70,046 of debt discount, leaving an unamortized balance of $119,930 at December 31, 2017.remaining $225,000 Settlement Amount.


11


NOTE 6 – SHAREHOLDERS’ EQUITY

Common shares issued for ServicesRestricted Stock Grants

The following table summarizes restricted common stock activity:

SUMMARY OF RESTRICTED COMMON STOCK

  Number of
Restricted
Shares
  Fair Value  Weighted
Average
Grant Date
Fair Value
 
          
Non-vested, September 30, 2021  8,750,000  $325,000  $0.03 
Granted  -   -   - 
Vested  (2,500,000)  (87,500)  0.04 
Forfeited  -   -   - 
Non-vested, March 31, 2022  6,250,000  $237,500  $0.04 

During the three and six months ended DecemberMarch 31, 2017,2022, the Company issued 120,000recorded $43,750 and $87,500, respectively, of stock compensation for the value of vested restricted common stock, and as of March 31, 2022, unvested compensation of $237,500 remained that will be amortized over the remaining vesting period, through March 2024.

In addition to the above grants, during the year ended September 30, 2021, the Company’s Board of Directors approved the issuance of a combined total of 41,353,731 restricted shares of itsthe Company’s common stock valued at $21,000 for services provided by accountingto its Officers and PSI consultants. The shares were valued atDirectors, all of which will only be issued upon the trading pricesale or merger of the commonCompany. No stock atcompensation was recorded relating to that grant as management feels it is a remote possibility that a sale or merger of the date of issuance.Company will happen within the next twelve months. The Company will account for the shares once they are granted to its Officers and Directors.

11

 

Stock Options

On December 22, 2010, effective retroactively as of June 30, 2010, the Company’s boardBoard of directorsDirectors approved the adoption of the “2010 Non-Qualified Stock Option Plan” (“2010 Option Plan”) by unanimous consent. The 2010 Option Plan was initiated to encourage and enable officers, directors, consultants, advisors and key employees of the Company to acquire and retain a proprietary interest in the Company by ownership of its common stock. A total of 7,500,000 of the authorized shares of the Company’s common stock may be subject to, or issued pursuant to, the terms of the plan. Effective January 1, 2018, the Board of Directors approved to increase the number of authorized shares of the Company’s common stock that may be subject to, or issued pursuant to, the terms of the plan from 7,500,000 to 30,000,000.

The Company’s policy is to recognize compensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisite service period for the entire award. Additionally, the Company’s policy is to issue new shares of common stock to satisfy stock option exercises. The Company applied fair value accounting for all share-based payments awards. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option-pricing model.

The table below summarizes the Company’s stock option activities for the threesix months ended DecemberMarch 31, 2017:2022:

SCHEDULE OF STOCK OPTION ACTIVITY

Number of

Option Shares

 

Exercise

Price Range

Per Share

 

Weighted

Average

Exercise

Price

 

Fair Value

at Date of Grant

 

Number of

Option Shares

 

Exercise

Price Range

Per Share

  Weighted Average
Exercise Price
 

 

 

 

 

 

 

 

       

Balance, September 30, 2017

6,822,500

$

0.10 - 2.00

$

0.51

$

1,865,628

Balance, September 30, 2021  5,277,738  $0.03 - 0.26  $0.15 

Granted

-

 

-

 

-

 

-

  -   -   - 

Cancelled

-

 

-

 

-

 

-

  -   -   - 

Exercised

-

 

-

 

-

 

-

  -   -   - 

Expired

-

 

-

 

-

 

-

  (850,000)  0.12 - 0.26   0.17 

Balance, December 31, 2017

6,822,500

$

0.10 – 2.00

$

0.51

$

1,865,628

Vested and exercisable, December 31, 2017

6,822,500

$

0.10 – 2.00

$

0.51

$

1,865,628

Balance, March 31, 2022  4,427,738  $0.03 - 0.26  $0.14 
Vested and exercisable, March 31, 2022  4,427,738  $0.03 - 0.26  $0.14 

 

 

 

 

 

 

 

            

Unvested, December 31, 2017

-

$

-

$

-

$

-

Unvested, March 31, 2022  -  $-  $- 

The aggregate intrinsic value for option shares outstanding at December 31, 2017 was $119,688.

The following table summarizes information concerning outstanding and exercisable options as of DecemberMarch 31, 2017:2022:

 

 

Options Outstanding

 

Options Exercisable

Range of

Exercise

Prices

 

Number

Outstanding

 

Average

Remaining

Contractual

Life

(in years)

 

Weighted

Average

Exercise

Price

 

Number

Exercisable

 

Average

Remaining

Contractual

Life

(in years)

 

Weighted

Average

Exercise

Price

 

 

 

 

 

 

 

 

 

 

 

 

 

$0.10 - 0.39

 

3,300,000

 

3.31

$

0.17

 

3,300,000

 

3.31

$

0.17

0.40 - 0.99

 

2,122,500

 

1.30

 

0.40

 

2,122,500

 

1.30

 

0.40

1.00 - 1.99

 

750,000

 

3.00

 

1.00

 

750,000

 

3.00

 

1.00

2.00

 

650,000

 

3.00

 

2.00

 

650,000

 

3.00

 

2.00

$0.01 - 2.00

 

6,822,500

 

2.62

$

0.51

 

6,822,500

 

2.62

$

0.51

SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS BY EXERCISE PRICE RANGE

   Options Outstanding  Options Exercisable 
Range of Exercise Prices  Number
Outstanding
  Average
Remaining
Contractual
Life (in years)
  Weighted
Average
Exercise Price
  Number
Exercisable
  Average
Remaining
Contractual
Life (in years)
  Weighted
Average
Exercise Price
 
                           
$0.03 - 0.26   4,427,738   1.33  $0.14   4,427,738   1.33  $0.14 
                           
$0.03 - 0.26   4,427,738   1.33  $0.14   4,427,738   1.33  $0.14 

During the six months ended March 31, 2022, 0 stock compensation was recorded for the value of options vesting during the period, and as of March 31, 2022, 0 unvested compensation remained that will be amortized over the remaining vesting period.

As of DecemberMarch 31, 2017,2022, there were 677,50025,572,262 shares of stock options remaining available for issuance under the 2010 Plan. The intrinsic value for option shares outstanding at March 31, 2022 was $3,125.


12


NOTE 6 – SHAREHOLDERS’ EQUITY (CONTINUED)

12

 

Stock Warrants

During the three months ended December, 31, 2017, warrants to purchase 924,286 shares of the Company’s common stock were exercised for $110,914.

The table below summarizes the Company’s warrants activities for the threesix months ended DecemberMarch 31, 2017:2022:

SCHEDULE OF WARRANT ACTIVITY

Number of

Warrant Shares

 

Exercise

Price Range

Per Share

 

Weighted

Average

Exercise

Price

 

Fair Value at Date of Issuance

 Number of
Warrant Shares
 Exercise
Price Range
Per Share
 Weighted Average
Exercise Price
 

 

 

 

 

 

 

 

       

Balance, September 30, 2017

64,161,304

$

0.12 - 1.00

$

0.24

$

2,151,219

Balance, September 30, 2021  32,032,075  $0.07 - 0.40  $0.16 

Granted

-

 

-

 

-

 

-

  -   -   - 

Cancelled

-

 

-

 

-

 

-

  -   -   - 

Exercised

(924,286)

 

0.12

 

0.12

 

-

  -   -   - 

Expired

(520,999)

 

0.45

 

0.45

 

-

  (3,775,278)  0.15   0.15 

Balance, December 31, 2017

62,716,019

$

0.12 - 1.00

$

0.24

$

2,151,219

Vested and exercisable, December 31, 2017

62,716,019

$

0.12 - 1.00

$

0.24

$

2,151,219

 

 

 

 

 

 

 

Unvested, December 31, 2017

-

$

-

$

-

$

-

Balance, March 31, 2022  28,256,797  $0.07 - 0.40  $0.16 
Vested and exercisable, March 31, 2022  28,256,797  $0.07 - 0.40  $0.16 

The aggregate intrinsic value for warrant shares outstanding December 31, 2017 was $1,811,221.

The following table summarizes information concerning outstanding and exercisable warrants as of DecemberMarch 31, 2017:2022:

SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS BY EXERCISE PRICE RANGE

 

 

Options Outstanding

 

Options Exercisable

Range of

Exercise

Prices

 

Number

Outstanding

 

Average

Remaining

Contractual

Life

(in years)

 

Weighted

Average

Exercise

Price

 

Number

Exercisable

 

Average

Remaining

Contractual

Life

(in years)

 

Weighted

Average

Exercise

Price

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$0.12 – 0.20

 

43,006,773

 

2.27

$

0.15

 

43,006,773

 

2.27

$

0.15

0.21 – 0.49

 

15,209,508

 

1.17

 

0.34

 

15,209,508

 

1.17

 

0.34

0.50 – 1.00

 

4,499,738

 

0.64

 

0.75

 

4,499,738

 

0.64

 

0.75

$0.12 – 1.00

 

62,716,019

 

1.89

$

0.24

 

62,716,019

 

1.89

$

0.24

   Warrants Outstanding  Warrants Exercisable 
Range of Exercise Prices  Number
Outstanding
  Average
Remaining
Contractual
Life (in years)
  Weighted
Average
Exercise Price
  Number
Exercisable
  Average
Remaining
Contractual
Life (in years)
  Weighted
Average
Exercise Price
 
                           
$0.070.20   27,306,797   1.47  $0.16   27,306,797   1.47  $0.16 
 0.210.40   950,000   0.96   0.33   950,000   0.96   0.33 
                           
$0.070.40   28,256,797   1.45  $0.16   28,256,797   1.45  $0.16 

There was 0 aggregate intrinsic value for warrant shares outstanding at March 31, 2022.

NOTE 7 – SEGMENT REPORTING

Reportable segments are components of an enterprise about which separate financial information is available and that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company'sCompany’s reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company. During the year ended September 30, 2017, the Company discontinued operations of its NPC segment (see Note 3).

The Company operates in the following business segments:

(i) Medical Devices: which it stems from PSI, its wholly-owned subsidiary it acquired on August 24, 2012, a developer, manufacturer, marketer and distributer of targeted Ultra Violet ("UV"(“UV”) phototherapy devices for the treatment of skin diseases.diseases, and for sanitation purposes.

(ii) Authentication and Encryption Products and Services: which it stems from StealthCo, its wholly-owned subsidiary formed on March 18, 2014. StealthCo engages2014, which has engaged in the business of selling, licensing or otherwise providing certain authentication and encryption products and services uponsince acquisition of certain assets from SMI.SMI on April 4, 2014.


13


NOTE 7 – SEGMENT REPORTING (CONTINUED)

13

 

The detailed segment information of the Company is as follows:

SCHEDULE OF ASSETS OF REPORTABLE SEGMENTS

Assets By Segment

                 
  March 31, 2022 
  Corporate  Medical
Devices
  Authentication
and Encryption
  Total 
ASSETS                
Current Assets                
Cash $4,703  $55,662  $4,113  $64,478 
Accounts receivable  -   956   -   956 
Inventories  -   27,157   -   27,157 
Total current assets  4,703   83,775   4,113   92,591 
                 
TOTAL ASSETS $4,703  $83,775  $4,113  $92,591 

Operations by Segment for the Three Months Ended March 31, 2022 and 2021

SCHEDULE OF OPERATIONS OF REPORTABLE SEGMENTS

                 
  For the Three Months Ended 
  March 31, 2022 
  Corporate  Medical
Devices
  Authentication
and Encryption
  Total 
             
Trade Sales $-  $99,990  $-  $99,990 
                 
Cost of goods sold  -   10,400   -   10,400 
                 
Gross profit  -   89,590   -   89,590 
                 
Operating expenses  63,132   244,380   3,190   310,702 
                 
Loss from operations $(63,132) $(154,790) $(3,190) $(221,112)

                 
  For the Three Months Ended 
  March 31, 2021 
  WCUI  PSI  Stealthco    
  Corporate  Medical
Devices
  Authentication
and Encryption
  Total 
             
Trade Sales $-  $51,650  $-  $51,650 
                 
Cost of goods sold  -   58,950   -   58,950 
                 
Gross profit  -   (7,300)  -   (7,300)
                 
Operating expenses  46,661   308,543   7,014   362,218 
                 
Loss from operations $(46,661) $(315,843) $(7,014) $(369,518)

14

 

Wellness Center USA, Inc.

Assets By Segments

 

 

 

 

 

 

 

 

 

 

 

December 31, 2017

 

 

Corporate

 

Medical

Devices

 

Authentication

and

Encryption

 

Total

ASSETS

 

 

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

 

 

Cash

$

15,800

$

2,367

$

5,427

$

23,594

Accounts receivable

 

-

 

-

 

5,000

 

5,000

Inventories

 

-

 

-

 

12,112

 

12,112

Prepaid expenses and other current assets

 

-

 

-

 

2,396

 

2,396

 

 

 

 

 

 

 

 

 

Total current assets

 

15,800

 

2,367

 

24,935

 

43,102

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

700

 

-

 

3,412

 

4,112

Other assets

 

15,000

 

1,760

 

-

 

16,760

 

 

 

 

 

 

 

 

 

Total other assets

 

15,700

 

1,760

 

3,412

 

20,872

 

 

 

 

 

 

 

 

 

TOTAL ASSETS

$

31,500

$

4,127

$

28,347

$

63,974

Wellness Center USA, Inc.

Operations by Segments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended

 

 

 

 

December 31, 2017

 

 

 

 

Corporate

 

Medical

Devices

 

Authentication

and

Encryption

 

Total

Sales:

 

 

 

 

 

 

 

 

Trade

$

-

$

-

$

15,500

$

15,500

Consulting services

 

-

 

-

 

11,000

 

11,000

Total Sales

 

-

 

-

 

26,500

 

26,500

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

-

 

-

 

16,992

 

16,992

 

 

 

 

 

 

 

 

 

Gross profit

 

-

 

-

 

9,508

 

9,508

 

 

 

 

 

 

 

 

 

Operating expenses

 

161,405

 

92,672

 

80,086

 

334,163

 

 

 

 

 

 

 

 

 

Loss from operations

$

(161,405)

$

(92,672)

$

(70,578)

$

(324,655)


14


NOTE 7 – SEGMENT REPORTING (CONTINUED)

Wellness Center USA, Inc.

Operations by Segments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended

 

 

 

 

December 31, 2016

 

 

 

 

Corporate

 

Medical

Devices

 

Authentication

and Encryption

 

Total

Sales:

 

 

 

 

 

 

 

 

Trade

$

-

$

84,000

$

5,000

$

89,000

Consulting services

 

-

 

-

 

14,125

 

14,125

Total Sales

 

-

 

84,000

 

19,125

 

103,125

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

-

 

40,033

 

20,467

 

60,500

 

 

 

 

 

 

 

 

 

 

 

Gross profit (loss)

 

-

 

43,967

 

(1,342)

 

42,625

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

236,905

 

65,656

 

114,002

 

416,563

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

$

(236,905)

$

(21,689)

$

(115,344)

$

(373,938)

Operations by Segment for the Six Months Ended March 31, 2022 and 2021

                 
  For the Six Months Ended 
  March 31, 2022 
  Corporate  Medical
Devices
  Authentication
and Encryption
  Total 
             
Trade Sales $-  $264,542  $-  $264,542 
                 
Cost of goods sold  -   36,400   -   36,400 
                 
Gross profit  -   228,142   -   228,142 
                 
Operating expenses  103,122   489,344   5,985   598,451 
                 
Loss from operations $(103,122) $(261,202) $(5,985) $(370,309)

                 
  For the Six Months Ended 
  March 31, 2021 
  WCUI  PSI  Stealthco    
  Corporate  Medical
Devices
  Authentication
and Encryption
  Total 
             
Trade Sales $-  $142,149  $-  $142,149 
                 
Cost of goods sold  -   139,050   -   139,050 
                 
Gross profit  -   3,099   -   3,099 
                 
Operating expenses  95,770   565,014   9,975   670,759 
                 
Loss from operations $(95,770) $(561,915) $(9,975) $(667,660)

NOTE 8 – LEGAL MATTERS

The Company is periodically engaged in legal proceedings arising from and relating to its business operations. WeExcept as otherwise described herein, we currently are not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or of our Company’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect on our financial condition or results of operations.

15

 

In June, 2015,

The Company continues efforts to preserve revenue and reduce operating expenses through actions including, but not limited to, facilities consolidation and staff reductions, which it hopes to implement through negotiated transactions with lessors, employees and other third parties. Such actions may result in disputes with and claims by such parties which, if not resolved through negotiations, may impact negatively the Company’s ability to continue as a going concern. To date, the Company has negotiated settlement of all ex-employee wage and its CEO receivedbenefits claims except for the claim filed with the Illinois Department of Labor asserting a formal order of investigation from the Chicago Regional Staffviolation of the SEC.Illinois Wage Payment and Collection Act by the Company’s former CEO. That claim alleges unpaid wages in the amount of $158,715 and unpaid vacation pay in the amount of $20,833 for a total amount of $179,548, as well as certain statutory damages including, but not limited to, 2% of the wages due per month plus attorneys’ fees if the ex-CEO elects to file suit for a violation of the Act and is successful in obtaining a judgment on his claim. The Company has filed its response to such claim with the Department denying the substantive allegations therein and its CEO cooperatedasserting certain factual and delivered requested documents, testimony, and tolling agreements.

In May, 2017,legal defenses, including breach of fiduciary duty, as a bar to all claimed compensation. The claim remains pending, but as the Staff issued a Wells Notice stating its preliminary determination to recommend an enforcement actiondate hereof, no suit has been filed against the Company and its CEOasserting a violation of the Act based on possible violationssaid claim.

As discussed in Note 5, on or about June 29, 2020, HHE filed case number 2020L006092 in the Circuit Court of Section 17(a)Cook County alleging failure to pay Base Rent and abandonment of certain office space in Hoffman Estates, Illinois subject to a Commercial Lease dated May 26, 2016 (the “HHE litigation”). HHE sought at least $672,888 in base rent and other amounts under the lease, as well as treble damages from our ex-CEO and two past Directors who were serving on our Board as of the Securities Act, Sections 15 (a) and 10(b)date of the Exchange Act,lease. On October 6, 2021, HHE and Rule 10b-5 thereunder. The Staff would allege, among other things, that periodic reports issued during 2013 and 2014 were misleading because they failedthe Company agreed to disclosea settlement on the terms discussed in Note 5 above. On February 10, 2022, the initial payment of $125,000 was paid to HHE (see Note 5).

On or mischaracterizedabout January 8, 2021, Periklis Papadopoulus, a former Director who was named as “salary”, “prepayments” or “loans,” several payments totaling $450,000 made to our CEO during those years without prior Board approval; that two press releases issuedan additional Defendant in 2015 touted shipments of several Psoria-Light devices that were not closed sales; and that we used an unregistered broker-dealer to identify and solicit potential investors during 2013, 2015 and 2017.

Subsequent discussions resulted in our submission of an Offer of Settlement (“Offer”) through an administrative cease and desist action on November 17, 2017. Pursuant to the Offer, we neither admit nor deny any of the proposed allegations, but are enjoined from violating the above-referenced Sections and Rule. The Offer imposes no financial penalties or sanctionsHHE litigation, filed a counterclaim against the Company seeking indemnification for attorneys’ fees he incurred in obtaining his dismissal from the HHE litigation. Subsequent to September 30, 2021, the Company settled the counterclaim by agreeing to pay $41,914, with $15,000 payable on or about January 4, 2022 and is subject to final SEC approval. The CEO did not jointhe balance in sixteen monthly installments commencing June 4, 2022, each in the Offeramount of $1,791. The settlement amount shall be reduced to $37,000 if it is paid prior to April 1, 2022, or $39,000 if paid before July 1, 2022. The Company agreed to entry of a judgment in the amount of $41,914 to secure payments under the settlement agreement. This amount is included in Accounts payable and may contest any action that may be asserted against him.accrued expenses on the accompanying Balance Sheets. Upon payment of the settlement, Papadopoulos will provide the Company with a satisfaction of judgment. During the three months ended March 31, 2022, but prior to April 1, 20122, the Company made payments totaling $37,000. This satisfied the judgment as of March 31, 2022 and the Company recorded a gain on settlement of debt of $4,914 during the three months ended March 31, 2022.


15


NOTE 9 – SUBSEQUENT EVENTS

On January 1, 2018,Subsequent to March 31, 2022, the Company entered into employment agreements with three employeesborrowed $150,000 from its officers and shareholders. All of SCI, under which their employment shall continue in effect for a periodthe loans are unsecured, have an interest rate of three years. Each agreement allows for a base salary that can increase eacheight percent and are due one year based on certain profitability goalsfrom the date of SCI or SCI products. Underissuance.

On April 1, 2022, the agreements,Company’s Board of Directors approved the Company will issue options to purchaseissuance of a combined total of 1,775,000 shares of its common stock. The options are exercisable over a term of five years, with an exercise price equal to the fair market value of the common stock on the date of grant. A combined total of 675,000 shares will vest in equal amounts over a three-month period, starting on January 1, 2018, with the remainder vesting in equal amounts over the following one year and two months. Further, provided the employees remain employed by the Company, beginning on January 1, 2018, they will be granted additional stock options to purchase up to an aggregate total of 250,0003,750,000 restricted shares of the Company’s common stock each quarter, exercisable over a five year period,to certain of its Officers and issuableDirectors for future services to be performed. The shares vest monthly from April 2022 through March 2025. The fair value of the shares on the last daydate of each quarter ending,grant was $187,500.

The Board also approved the issuance of a combined total of 7,060,000 restricted shares of the Company’s common stock to certain of its Officers and Directors in connection with an exercise price to be set at the thentheir officer and shareholder loans. The shares vested upon grant and had a fair market value and based on the closing trading price ondate of grant of $353,000. These shares were granted from the last day41,353,731 deferred restricted shares of each quarter end. All Options shall accelerate and become fully vestedthe Company’s common stock which will only be issued upon the sale or change of controlmerger of the Company.Company (see Note 6 – Restricted Stock Grants), thus reducing the number of shares that can be issued under that certain condition.

 

In January 2018,During the year ended September 30, 2021, the Company entered into a promissory note payablean agreement with one of its investors.a consulting firm under which the firm would provide certain services for the Company. Under the agreement, the Company borrowed $50,000. The note accrued interest at 8% per annum, is unsecured and is due in January 2019.

In February 2018, the Company entered into a promissory note payable agreement with one of its investors. Under the agreement, the Company borrowed $37,500. The note accrued interest at 8% per annum, is unsecured and is due in February 2019.

In February 2018, the Company entered into a promissory note payable agreement with one of its investors. Under the agreement, the Company borrowed $30,000. The note accrued interest at 8% per annum, is unsecured and is due in February 2019.

Subsequent to December 31, 2017, the Company issued 30,000 shares of its common stock for services provided by a PSI consultant. The shares were valued at the trading price of the common stock at the date of issuance.

Subsequent to December 31, 2017, warrants were exercised to purchase 416,667firm could earn 1.0 million restricted shares of the Company’s common stock for $50,000.completing certain services. In April 2022, the Company’s Board of Directors approved the issuance of the 1.0 million shares once the services had been completed. The shares vested upon grant and had a fair value on the date of grant of $50,000.


16


16

ITEM 2. MANAGEMENT'SMANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward Looking Statements

Except for historical information, the following discussion contains forward-looking statements based upon current expectations that involve certain risks and uncertainties. Such forward-looking statements include statements regarding, among other things, (a) our projected sales and profitability, (b) our growth strategies, (c) anticipated trends in our industry, (d) our future financing plans, (e) our anticipated needs for working capital, (f) our lack of operational experience and (g) the benefits related to ownership of our common stock. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. This information may involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from the future results, performance, or achievements expressed or implied by any forward-looking statements. These statements may be found under “Description of Business,” and “Analysis of Financial Condition and Results of Operations”, as well as in this Report generally. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors, including, without limitation, the risks outlined under “Risk Factors” in our Annual Report on Form 10-K and in other Reports we have filed with the Securities and Exchange Commission, as well as matters described in this Report generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this Report will in fact occur as projected.

The following discussion and analysis provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. The discussion should be read along with our financial statements and notes thereto. This section includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

Description of Business

BackgroundBackground.

Wellness Center USA, Inc. ("WCUI"(“WCUI” or the “Company”) was incorporated in June 2010 under the laws of the State of Nevada. The CompanyWe initially engaged in online sports and nutrition supplements marketing and distribution. The CompanyWe subsequently expanded into additional businesses within the healthcare and medical sectors through acquisitions, including Psoria-Shield Inc. (“PSI”), National Pain Centers, Inc. (“NPC”) and StealthCo Inc. (“SCI”), d/b/a Stealth Mark, Inc. On August 11, 2017, the Company entered into an agreement to sell 100% of the issued and outstanding shares of NPC, which has been accounted for as a discontinued operation on the condensed consolidated financial statements for the three months ended December 31, 2016. See Note 3 for details relating to the sale.

The Company currently operates in the followingtwo business segments: (i) distribution of targeted Ultra Violet ("UV"(“UV”) phototherapy devices for dermatology;dermatology and sanitation purposes; and (ii) authentication and encryption products and services. The segments are operated, respectively,conducted through our wholly-owned subsidiaries, PSI and SCI.

PSI

PSI was incorporated under the laws of the state of Florida on June 17, 2009. On August 24, 2012, weWe acquired all of the issued and outstanding shares of stock in PSI. PSI ison August 24, 2012.

Joint Ventures

In December 2018, PSI entered into a wholly­owned subsidiaryJoint Venture Agreement with GEN2 for further development, marketing, licensing and/or sale of PSI technology and products to be conducted through NEO Phototherapy, Inc. (“NEO”). PSI and GEN2 were the members of NEO, owning 50.5% and 36.0%, respectively. As of April 30, 2020, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%.

17

Effective April 30, 2020, the joint venture with GEN2 was reorganized. GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and operatedproducts developed by Psoria Development Company LLC, an Illinois limited liability companythe joint venture. During the six months ended March 31, 2022, PSI recorded a loss of $481,354 relating to its operations, of which $146,019 was allocated to the non-controlling interest.

As of September 30, 2020, GEN2 had received $975,000 of investments to contribute to NEO. Repayment of the $975,000 investment will begin through and upon the date which PSI has realized and retained cumulative net income/distributable cash in the amount of $300,000. The minority interest of PSI ownership consists of accredited investors, and investment participation of $750,000 from several WCUI officers and directors, including Calvin R. O’Harrow, William Kingsford and Roy M. Harsch.

Protec

In May 2020, the Company’s subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. (“PDC”Protec”), a joint venture between WCUI/company formed in April 2020. As of September 30, 2020, PSI andhad contributed $191,000 to Protec with the Company’s share being approximately 32%, based on its PSI ownership. The Medical Alliance, Inc.,remaining 30% share is attributed to PSI’s minority shareholders. During the six months ended December 31, 2020, Protec received an additional $120,000 from non-affiliated investors. The additional investments gave the non-controlling interests a Florida corporation (“TMA”).68% ownership interest in Protec. During the six months ended March 31, 2022, Protec recorded a loss of $7,990, of which $4,244 was allocated to the non-controlling interests.

Psoria-Light

PSI designs, develops and markets a targeted ultraviolet (“UV”) phototherapy device called the Psoria­Light.Psoria-Light. The Psoria­LightPsoria-Light is designated for use in targeted PUVA photochemistry and UVB phototherapy and is designed to treat certain skin conditions including psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma.

Psoriasis, eczema, and vitiligo, are common skin conditions that can be challenging to treat, and often cause the client significant psychosocial stress. Clients may undergo a variety of treatments to address these skin conditions, including routine consumption of systemic and biologic drug therapies which are highly toxic, reduce systemic immune system function, and come with a host of chemotherapy­likechemotherapy-like side effects. Ultraviolet (UV) phototherapy is a clinically validated alternate treatment modality for these disorders.


17


Traditionally, “non-targeted” UV phototherapy was administered by lamps that emitted either UVA or UVB light to both diseased and healthy skin. While sunblocks or other UV barriers may be used to protect healthy skin, the UV administered in this manner must be low dosage to avoid excessive exposure of healthy tissue. Today, “targeted” UV phototherapy devices administer much higher dosages of light only to affected tissue, resulting in “clearance” in the case of psoriasis and eczema, and “repigmentation” in the case of vitiligo, at much faster rates than non-targeted (low dosage) UV treatments.

Targeted UV treatments are typically administered to smaller total body surface areas, and are therefore used to treat the most intense parts of a client’s disease. Non-targeted UV treatment is typically used as a follow-up and for maintenance, capable of treating large surfaces of the body. Excimer laser devices (UVB at 308nm) are expensive and consume dangerous chemicals (Xenon and Chlorine). Mercury lamp devices (UVB and/or UVA) require expensive lamp replacements regularly and require special disposal (due to mercury content). Additionally, mercury lamp devices typically deliver wavelengths of light below 300nm. While within the UVB spectrum, it has been shown that wavelengths below 300nm produce significantly more “sunburn” type side effects than do wavelengths between 300 and 320nm without improvement in therapeutic benefit.

The Psoria-Light is a targeted UV phototherapy device that produces UVB light between 300 and 320 nm as well as UVA light between 350 and 395nm. It does not require consumption of dangerous chemicals or require special environmental disposal, and is cost effective for clinicians, which should result in increased patient access to this type of treatment. It has several unique and advanced features that we believe will distinguish it from the non-targeted and targeted UV phototherapy devices that are currently being used by dermatologists and other healthcare providers. These features include the following: the utilization of deep narrow-band UVB (“NB-UVB”) LEDs as light sources; the ability to produce both UVA or NB-UVB therapeutic wavelengths; an integrated high resolution digital camera and client record integration capabilities; the ability to export to an external USB memory device a PDF file of treatment information including a patent pending graph that includes digital images plotted against user tracked metrics which can be submitted to improve medical reimbursements; an accessory port and ability to update software; ease of placement and portability; advanced treatment site detection safety sensor; international language support; a warranty which includes the UV lamp(s); and a non-changeable treatment log (that does not include HIPPA information).

18

 

The Psoria-Light consists of three components: a base console, a color display with touchscreen control, and a hand-held delivery device with a conduit (or tether) between the handheld device and the base console. PSI requires clearance by the United States Food and Drug Administration (“FDA”) to market and sell the device in the United States as well as permission from TUV SUD America Inc., PSI’s Notified Body, to affix the CE mark to the Psoria-Light in order to market and sell the device in countries of the European Union.

To obtain FDA clearance and permission to affix the CE mark, PSI was required to conduct EMC and electrical safety testing, which it completed in the second quarter of 2011. PSI received FDA clearance on February 11, 2011 (no. K103540) and was granted permission to affix the CE mark on November 10, 2011. In its 510(k) application with the FDA (application number K103540), PSI asserted that the Psoria-Light was “substantially equivalent” in intended use and technology to two predicate devices, the X -Trac Excimer Laser, which has wide acceptance in the medical billing literature and has a large installed base in the U.S., and the Dualight, another competing targeted UV phototherapy device.

PSI has established an ISO 13485 compliant quality system for the Psoria-Light, which was first audited in the third quarter of 2011. This system is intended to ensure PSI devices will be manufactured in a controlled and reliable environment and that its resources follow similar practices and is required for sales in countries requiring a CE mark. PSI has also received Certified Space Technology designation from the Space Foundation, based on PSI’s incorporation of established NASA-funded LED technology.

PSI began Psoria-Light Beta deployment in January 2012. It is currently operating at a loss, and there is no assurance that its business development plans and strategies will ever be successful. PSI’s success depends upon the acceptance by healthcare providers and clients of Psoria-Light treatment as a preferred method of treatment for psoriasis and other UV-treatable skin conditions. Psoria-Light treatment appears to have been beneficial to clients, without demonstrable harmful side effects or safety issues, as evidenced by more than 10,000 treatments completed on more than 1,000 clients, domestically and Mexico, since 2012. In order for the Company to continue PSI operations, it will need additional capital and it will have to successfully coordinate integration of PSI operations without materially and adversely affecting continuation and development of other Company operations.

SCI

SCI was incorporated under the laws of the state of Illinois on March 18, 2014. SCI acquired certain Stealth Mark assets on April 4, 2014 and operates as a wholly-owned subsidiary of the Company. It is a Tennessee-based provider of: a) Stealth Mark encryption and authentication solutions offering advanced technologies within the security and supply chain management vertical sectors(Microparticles)(Intelligent Microparticles), and b) advanced data intelligence services offering proprietary, unprecedented, and actionable technology for industries, companies, and agencies on a global scale (ActiveDutyTMActiveDuty™).


18


Intelligent Microparticles

SCI provides clients premiere authentication technology for the protection of a variety of products and brands from illicit counterfeiting and diversion activities. Its technology is applicable to a wide range of industries affected by counterfeiting, diversion and theft including, but not limited to, pharmaceuticals, defense/aerospace, automotive, electronics, technology, consumer and personal care goods, designer products, beverage/spirits, and many others.

SCI delivers the client a complete, simple to use, easy to implement, and cost effective turnkey system that is extremely difficult to compromise. SCI’s technology includes a combination of proprietary software and intelligent microparticle marks that are unduplicatable and undetectable to the human eye. These taggants are created with proprietary materials that create unique numerical codes that are assigned meaning by the client and are machine readable without the use of rare earth or chemical tracers. They have been used in covert and overt operations with easy to implement technology and do-it-yourself in-the-field forensic caliber verification.

19

 

In April 2018, the Company’s subsidiary, SCI, concluded licensing of a patent for technology that is the next generation of Stealth Mark. Working with researchers at the Oak Ridge National Labs, the patent signifies development of a new technology that will generate an invisible marking system with attributes currently unavailable in the anti-counterfeit marketplace today. The formula and techniques have been shown through extensive testing to be resilient to manufacturing processes and can be used on a wide range of materials from woven and non-woven fabrics, cardboard, metal, concrete, plastics, leather, wood, and paper. In addition, the complexity of the information that can be encoded with the system makes counterfeiting difficult.

ActiveDutyTMActiveDuty™

SCI’s ActiveDutyTMActiveDuty™ data intelligence servicesoffer unique, unprecedented, actionable technology for industries, companies, and agencies on a global scale. Comprised of a suite of powerful analytical tools, including artificial intelligence and social-psychology, the service provides timely and actionable intelligence to clients. ActiveDutyTMActiveDuty™ is adaptable to a broad spectrum of illicit activities within both private and public sectors such as, but not limited to, counterfeiting, sex and human trafficking, money laundering, and a variety of other markets.

The proprietary algorithmic architecture of ActiveDutyTMActiveDuty™ creates the first systemic reporting mechanism to deliver strategic and tactical results supported by an intense worldwide analysis of patterns of human behavior. The ActiveDutyTMActiveDuty™ global framework is heuristic in nature, capable of comprehending big data across the digital spectrum and speaks all the major languages. Up until now, there has not existed a unified system that could actively measure this lifecycle that is a collection of discreet and seemingly random behaviors of criminals anywhere within the digital domain. Criminals change their identities but not their basic behaviors.

SCI iswas managed initially by its CEO, Ricky Howard. Mr. Howard, haswho brought over thirty years of experience in operations management and executive positions in a variety of industries ranging from entrepreneurial startups to Fortune 500 companies. He joined Stealth Mark as V.P. of Operations at the early stage of development in 2006 and played an integral role in bringing the company’s capabilities to its present status including design and creation of its manufacturing capabilities, implementation of its ERP inventory controls system, software and hardware development, marketing and sales materials processes and day-to-day operational procedures and processes. In November 2018, Mr. Howard passed away suddenly and Mr. O’Harrow took over operations of SCI’s business on an interim basis.

Analysis of Financial Condition and Results of Operations

Results of Operations for the three months ended DecemberMarch 31, 20172022 compared to the three months ended DecemberMarch 31, 2016.2021.

Revenue and Cost of Goods Sold

Revenue for the three months ended DecemberMarch 31, 20172022 and 20162021 was $26,500$99,990 and $103,125,$51,650, respectively. The decrease of $76,625 was dueincrease in revenue in 2022 related to the decreaseincrease in revenues at PSI as they had no revenue duringdue to the three months ended December 31, 2017, but had $84,000roll-out of revenue during the three months ended December 31, 2016.their new Aurora medical device. Cost of sales for the three months ended DecemberMarch 31, 20172022 and 2016,2021 was $16,992$10,400 and $60,500,$58,950, respectively. Gross profit (loss) for the three months ended DecemberMarch 31, 20172022 and 2016,2021 was $9,508$89,590 and $42,625,$(7,300), respectively. The reason for the gross profit decrease of $33,117loss in 2021 was primarily due to the decrease in revenuesinventory write downs of PSI during the three months ended December 31, 2017.$50,000.

In June 2017, PSI entered into a pilot program agreement with a Chicago government healthcare organization under which the customer purchased one Psoria Light (PL 1000) to conduct therapy and evaluate the device's efficacy and functionality for a period of 60 days. Under the agreement, at the end of the pilot program, if the customer was satisfied with the first unit, PSI would receive a purchase order for an additional 15 units. PSI shipped the first unit to the customer in early August 2017, it passed their electrical safety inspection and they were ready to commence training.

The pilot program has been extended and continues. If concluded favorably, units would be supplied to individual clinics on a scheduled basis predicated upon in-service and educational program coordination. The objective would be to have all selected hospital system clinics equipped with the PL 1000 as medical staff become properly trained to treat previously identified skin conditions, but there can be no assurance this will occur.


19


Operating Expenses

Operating expenses for the three months ended DecemberMarch 31, 20172022 and 20162021 were $334,163$310,702 and $416,563,$362,218, respectively. The decrease in operating expenses of $82,400in 2022 was due primarily to the reduction ofdecrease in consulting fees and professional fees during the three months ended December 31, 2017.employee-related costs.

Other Income (Expenses)

Other expenses during the three months ended DecemberMarch 31, 20172022 consisted of $70,047$ $44,664 of amortizationinterest expense and $4,375 of debt discount and $3,300 of interest expense. There was no other income or expenseamortization, totaling to $49,039. Other expenses during the three months ended DecemberMarch 31, 2016.2021 consisted of $31,993 of interest expense. Other income during the three months ended March 31, 2022 consisted of a gain of $4,914 on the settlement of debt.

20

 

Net Loss from Continuing Operations

Our net loss from continuing operations for the three months ended DecemberMarch 31, 20172022 was $398,002,$265,237, compared to a net loss from continuing operations of $373,938$401,511 for the three months ended DecemberMarch 31, 2016.2021. The increasedecrease in the net loss of $24,064in 2022 was primarily due to the decreaseincrease in revenues and gross profit and the decrease in operating expenses.

Results of Operations for the six months ended March 31, 2021 compared to the six months ended March 31, 2020.

Revenue and Cost of Goods Sold

Revenue for the six months ended March 31, 2022 and 2021 was $264,542 and $142,149, respectively. The increase in otherrevenue in 2022 related to the increase in revenues at PSI due to the roll-out of their new Aurora medical device. Cost of sales for the six months ended March 31, 2022 and 2021 was $36,400 and $139,050, respectively. Gross profit for the six months ended March 31, 2022 and 2021 was $228,142 and $3,099, respectively. The reason for the low margin in 2021 was due to inventory write downs of $100,000.

Operating Expenses

Operating expenses offset byfor the six months ended March 31, 2022 and 2021 were $598,451 and $670,759, respectively. The decrease in operating expenses in 2022 was due primarily to the decrease in consulting fees and employee-related costs.

Other Income (Expenses)

Other expenses during the six months ended March 31, 2022 consisted of $86,251 of interest expense and $8,750 of debt discount amortization, totaling to $95,001. Other expenses during the six months ended March 31, 2021 consisted of $58,151 of interest expense. Other income during the six months ended March 31, 2022 consisted of a gain of $4,914 on the settlement of debt.

Net Loss

Our net loss for the six months ended March 31, 2022 was $460,396, compared to a net loss of $725,811 for the six months ended March 31, 2021. The decrease in the net loss in 2022 was primarily due to the increase in revenues and gross profit and the decrease in operating expenses.

Results of Operations by Segment

The Company currently maintains two business segments:

(i)Medical Devices: which it provided through PSI, its subsidiary acquired on August 24, 2012, a developer, manufacturer, marketer and distributer of targeted Ultra Violet (“UV”) phototherapy devices for the treatment of skin diseases; and

(ii)Authentication and Encryption Products and Services: which it provided through SCI, its wholly-owned subsidiary that on April 4, 2014 acquired certain assets of SMI Holdings, Inc. d/b/a Stealth Mark, Inc., including Stealth Mark tradenames and marks, and related encryption and authentication solutions offering advanced product security technologies within the security and supply chain management vertical sectors.

21

 

(i)Medical Devices: which it provided through PSI, its wholly-owned subsidiary acquired on August 24, 2012, a developer, manufacturer, marketer and distributer of targeted Ultra Violet ("UV") phototherapy devices for the treatment of skin diseases; and  

(ii)Authentication and Encryption Products and Services: which it provided through SCI, its wholly-owned subsidiary that on April 4, 2014 acquired certain assets of SMI Holdings, Inc. d/b/a Stealth Mark, Inc., including Stealth Mark tradenames and marks, and related encryption and authentication solutions offering advanced product security technologies within the security and supply chain management vertical sectors.  

The detailed segment information of the Company is as follows:

Wellness Center USA, Inc.

Operations by Segments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended

 

 

 

 

December 31, 2017

 

 

 

 

Corporate

 

Medical

Devices

 

Authentication

and

Encryption

 

Total

Sales:

 

 

 

 

 

 

 

 

Trade

$

-

$

-

$

15,500

$

15,500

Consulting services

 

-

 

-

 

11,000

 

11,000

Total Sales

 

-

 

-

 

26,500

 

26,500

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

-

 

-

 

16,992

 

16,992

 

 

 

 

 

 

 

 

 

Gross profit

 

-

 

-

 

9,508

 

9,508

 

 

 

 

 

 

 

 

 

Operating expenses

 

161,405

 

92,672

 

80,086

 

334,163

 

 

 

 

 

 

 

 

 

Loss from operations

$

(161,405)

$

(92,672)

$

(70,578)

$

(324,655)


20


Wellness Center USA, Inc.

Operations by Segments

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended

 

 

December 31, 2016

 

 

Corporate

 

Medical

Devices

 

Authentication

and

Encryption

 

Total

Sales:

 

 

 

 

 

 

 

 

Trade

$

-

$

84,000

$

5,000

$

89,000

Consulting services

 

-

 

-

 

14,125

 

14,125

Total Sales

 

-

 

84,000

 

19,125

 

103,125

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

-

 

40,033

 

20,467

 

60,500

 

 

 

 

 

 

 

 

 

Gross profit (loss)

 

-

 

43,967

 

(1,342)

 

42,625

 

 

 

 

 

 

 

 

 

Operating expenses

 

236,905

 

65,656

 

114,002

 

416,563

 

 

 

 

 

 

 

 

 

Loss from operations

$

(236,905)

$

(21,689)

$

(115,344)

$

(373,938)

Operations by Segment for the Three Months Ended March 31, 2022 and 2021

  For the Three Months Ended 
  March 31, 2022 
  Corporate  Medical
Devices
  Authentication
and Encryption
  Total 
             
Trade Sales $-  $99,990  $-  $99,990 
                 
Cost of goods sold  -   10,400   -   10,400 
                 
Gross profit  -   89,590   -   89,590 
                 
Operating expenses  63,132   244,380   3,190   310,702 
                 
Loss from operations $(63,132) $(154,790) $(3,190) $(221,112)

  For the Three Months Ended 
  March 31, 2021 
  WCUI  PSI  Stealthco    
  Corporate  Medical
Devices
  Authentication
and Encryption
  Total 
             
Trade Sales $-  $51,650  $-  $51,650 
                 
Cost of goods sold  -   58,950   -   58,950 
                 
Gross profit  -   (7,300)  -   (7,300)
                 
Operating expenses  46,661   308,543   7,014   362,218 
                 
Loss from operations $(46,661) $(315,843) $(7,014) $(369,518)

Revenue for the Medical Devices segment for the three months ended DecemberMarch 31, 20162022 and 2021 was $84,000.$99,990 and $51,650, respectively. The Medical Devices segment had no revenue, cost ofincrease in 2022 was due to the increase in trade sales or gross profit for the three months ended December 31, 2017.at PSI. Cost of goods sold for the three months ended DecemberMarch 31, 20162022 and 2021 was $40,033. Gross$10,400 and $58,950, respectively, and the gross profit for(loss) was $89,590 and $(7,300), respectively. The negative gross profit was primarily due to the three months ended December 31, 2016 was $43,967.write down of inventories of $50,000 during the quarter. Operating expenses for the three months ended DecemberMarch 31, 20172022 and 20162021 was $92,672$244,380 and $65,656,$308,543, respectively. The increasedecrease in operating expenses of $27,016 in fiscal 20172022 was primarily due primarily to the increasedecrease in consulting fees.employee-related costs and contract labor. The loss from operations for the three months ended DecemberMarch 31, 20172022 and 20162021 was $92,672$154,790 and $21,689,$315,843, respectively.

RevenueThere was no revenue or cost of goods sold for the Authentication and Encryption segment for the three months ended DecemberMarch 31, 20172022 and 2016 was $26,500 and $19,125, respectively. The increase of $7,375 was due to the increase in trade sales during fiscal 2017. Cost of goods sold for the three months ended December 31, 2017 and 2016 was $16,992 and $20,467, respectively, and the gross profit (loss) was $9,508 and $(1,342), respectively. The gross profit increase in fiscal 2017 was primarily due to the increase in sales in fiscal 2017.2021. Operating expenses for the three months ended DecemberMarch 31, 20172022 and 20162021 was $80,086$3,190 and $114,002,$7,014, respectively. The decrease in operating expenses of $33,916 in fiscal 20172022 was primarily due primarily to the decrease in consultingemployee-related costs. The loss from operations for the three months ended DecemberMarch 31, 20172022 and 20162021 was $70,578$3,190 and $115,344,$7,014, respectively.

22

 

The Corporate segment primarily provides executive management services for the Company. Operating expenses for the three months ended DecemberMarch 31, 20172022 and 20162021 was $161,405$63,132 and $236,905,$46,661, respectively. The decreaseincrease in operating expenses of $75,500 in fiscal 20172022 was primarily due primarily to the decreaseincrease in professional fees and consulting fees.stock compensation. The loss from operations for the three months ended DecemberMarch 31, 20172022 and 20162021 was $161,405$63,132 and $236,905,$46,661, respectively.

Operations by Segment for the Six Months Ended March 31, 2022 and 2021

  For the Six Months Ended 
  March 31, 2022 
  Corporate  Medical
Devices
  Authentication
and Encryption
  Total 
             
Trade Sales $-  $264,542  $-  $264,542 
                 
Cost of goods sold  -   36,400   -   36,400 
                 
Gross profit  -   228,142   -   228,142 
                 
Operating expenses  103,122   489,344   5,985   598,451 
                 
Loss from operations $(103,122) $(261,202) $(5,985) $(370,309)

  For the Six Months Ended 
  March 31, 2021 
  WCUI  PSI  Stealthco    
  Corporate  Medical
Devices
  Authentication
and Encryption
  Total 
             
Trade Sales $-  $142,149  $-  $142,149 
                 
Cost of goods sold  -   139,050   -   139,050 
                 
Gross profit  -   3,099   -   3,099 
                 
Operating expenses  95,770   565,014   9,975   670,759 
                 
Loss from operations $(95,770) $(561,915) $(9,975) $(667,660)

Revenue for the Medical Devices segment for the six months ended March 31, 2021 was $264,542 and $142,149, respectively. The increase in 2022 was due to the increase in trade sales at PSI. Cost of goods sold for the six months ended March 31, 2022 and 2021 was $36,400 and $139,050, respectively, and the gross profit was $228,142 and $3,099, respectively. The low profit margin in 2022 was primarily due to the write down of inventories of $100,000 in 2021. Operating expenses for the six months ended March 31, 2022 and 2021 was $489,344 and $565,014, respectively. The decrease in operating expenses in 2022 was primarily due to the decrease in employee-related costs and contract labor. The loss from operations for the six months ended March 31, 2022 and 2021 was $261,202 and $561,915, respectively.

There was no revenue or cost of goods sold for the Authentication and Encryption segment for the six months ended March 31, 2022 and 2021. Operating expenses for the six months ended March 31, 2022 and 2021 was $5,985 and $9,975, respectively. The decrease in operating expenses in 2022 was primarily due to the decrease in employee-related costs. The loss from operations for the six months ended March 31, 2021 and 2020 was $5,985 and $9,975, respectively.

23

 

The Corporate segment primarily provides executive management services for the Company. Operating expenses for the six months ended March 31, 2022 and 2021 was $103,122 and $95,770, respectively. The increase in operating expenses in 2022 was primarily due to the increase in professional fees and stock compensation. The loss from operations for the six months ended March 31, 2022 and 2021 was $103,122 and $95,770, respectively.

Liquidity and Capital Resources

Liquidity is the ability of a company to generate adequate amounts of cash to meet its cash needs.Going Concern

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying condensed consolidated financial statements, the Company has not yet generated significant revenues and has incurred recurring net losses. During the threesix months ended DecemberMarch 31, 2017,2022, the Company incurred a net loss from continuing operations of $398,002$460,396 and used cash in operations of $147,189,$438,201, and had a shareholders’ deficit of $556,537$3,719,244 as of DecemberMarch 31, 2017.2022. In addition, loans payable of $1,816,250 and payroll taxes of $66,834 are past due. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.


21


As of DecemberAt March 31, 2017, our cash balance was $23,594. Our current2022, the Company had cash on hand in the amount of $64,478. The ability to continue as a going concern is not sufficient to maintain our daily operations for the next 12 months unlessdependent on the Company is able to generate positive cash flows from operating activities. If needed, management intends to raiseattaining and maintaining profitable operations in the future and raising additional capital soon to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, we have funded our operations primarily through equity financingand debt financings and we expect to fund our daily operations through next 12 months and duringcontinue to rely on these sources of capital in the threefuture. During the six months ended DecemberMarch 31, 2017, received $141,414 through debt financing and the exercise of stock warrants. However no assurance can be given that we will be successful in raising sufficient capital through debt or equity financing, or that we will be able to raise the required working capital on terms favorable, or that such working capital will be available on any terms when needed during next 12 months. Any failure to secure sufficient debt or equity financing may force2022, the Company to modify its business plan. In addition, we have incurred recurring lossesreceived $326,000 through short-term loans from inceptionofficers and such losses are expected to continue for the foreseeable futureshareholders and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations.$304,600 from a U.S. SBA loan payable.

No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stock holders,stockholders, in case of equity financing.

The Company’s independent registered public accounting firm, in their report on the Company’s consolidated financial statements for the year ended September 30, 2017, has expressed substantial doubt about the Company’s ability to continue as a going concern.

Comparison of threesix months years ended DecemberMarch 31, 20172022 and 20162021

As of DecemberMarch 31, 2017,2022, we had $23,594$64,478 in cash, negative working capital of $577,409$3,414,644 and an accumulated deficit of $19,484,590.$28,699,761.

As of DecemberMarch 31, 2016,2021, we had $154,724$146,139 in cash, negative working capital of $855,180$2,813,176 and an accumulated deficit of $17,950,799.$27,977,238.

Cash flows used in operating activities

During the threesix months ended DecemberMarch 31, 2017,2022, the Company used cash flows in continuing operating activities of $147,189$438,201, compared to $231,092$565,181 used in the threesix months ended DecemberMarch 31, 2016.2021. During the threesix months ended DecemberMarch 31, 2017,2022, the Company incurred a net loss of $398,002$460,396 and $92,060$96,250 of non-cash expenses, compared to a net loss of $415,500$725,811 and $40,851$211,975 of non-cash expenses during the three month periodsix months ended DecemberMarch 31, 2016.2021.

Cash flows used in investing activities

During the threesix months ended DecemberMarch 31, 2016, we had purchases of property2022 and equipment of $2,250. We2021, the Company had no cash flows from investing activities during the three months ended December 31, 2017.activities.

Cash flows provided by financing activities

During the threesix months ended DecemberMarch 31, 2017, we2022, the Company had proceeds from loans payable from officers and shareholders of $30,500$326,000 and proceeds$304,600 from a U.S. SBA loan payable, and repaid $160,000 of $110,914its loans payable from the exercise of stock warrants.officers and shareholders. During the threesix months ended DecemberMarch 31, 2016, we2021, the Company had proceeds from common stock issuableloans payable from officers and shareholders of $309,000.$660,000.

24

 

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Summary of Critical Accounting Policies.

The Company has identified critical accounting policies that, as a result of the judgments, uncertainties, uniqueness and complexities of the underlying accounting standards and operations involved could result in material changes to its financial condition or results of operations under different conditions or using different assumptions. The Company'sCompany’s most critical accounting policies include, but are not limited to, those related to fair value of financial instruments, revenue recognition, stock basedstock-based compensation for obtaining employee services, and equity instruments issued to parties other than employees for acquiring goods or services. Details regarding the Company'sCompany’s use of these policies and the related estimates are described in the Company'sCompany’s Annual Report on Form 10-K for the fiscal year ended September 30, 2017,2021, filed with the Securities and Exchange Commission on February 20, 2018.15, 2022. There have been no material changes to the Company'sCompany’s critical accounting policies that impact the Company'sCompany’s financial condition, results of operations or cash flows for the threesix months ended DecemberMarch 31, 2017.2022.


22


Recently Issued Accounting Pronouncements

See Management’s discussion of recent accounting policies included in footnote 2 to the condensed consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required for smaller reporting Companies.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and ProceduresProcedures.

Regulations under the Securities Exchange Act of 1934 (the “Exchange Act”) require public companies to maintain “disclosure controls and procedures,” which are defined as controls and other procedures that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission'sCommission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer'sissuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. A material weakness is a control deficiency (within the meaning of the Public Company Accounting Oversight Board (PCAOB) Auditing Standard No. 2)2201) or combination of control deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected.

The Company carried out an evaluation, with the participation of the Company’s management, including the Company’s Chief Executive Officer (“CEO”), of the effectiveness of the Company’sWe have identified material weaknesses in our disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of September 30, 2017, the end of the period covered by this report. Based upon that evaluation, the Company’s CEO concluded that the Company’sand internal control over financial reporting.

Maintaining effective internal control over financial reporting and effective disclosure controls and procedures are necessary for us to produce reliable financial statements. We have evaluated our internal control over financial reporting and our disclosure controls and procedures and concluded that they were not effective at theas of March 31, 2022.

A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable assurance level due to thepossibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses described below:

1.we identified are (i) The Company does not have an independent audit committee; (ii) the Company does not have written documentation of its internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act which is applicable to the Company. Management evaluated the impact of its failure to have written documentation of its internal controls and procedures on its assessment of its disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.  

2.The Company’s board of directors has no audit committee, independent director or member with financial expertise which causes ineffective oversight of the Company’s external financial reporting and internal control over financial reporting.  

3.procedures; (iii) The Company does not have sufficient segregation of duties within its accounting functions, which is a basic internal control. Due to its size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of its failure to have segregation of duties on its assessment of its disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.  

4.functions; (iv) The Company does not have sufficient segregationhas insufficient full-time personnel with an appropriate level of duties so that one person can initiate, authorizecurrent U.S. GAAP and execute transactions.  

5.Lack of Board of Director approval of debtSEC reporting requirements to timely meet regulatory filing requirements, and equity instruments before issuance.  

6.Weaknesses in the(v) The Company had ineffective controls over press releases before being disseminated.  

7.Absence of a compensation committee to approve all officer compensation.  

In light of the material weaknesses, the management of the Company performed additional analysisour financial statement close and other post-closing procedures to ensure our consolidated financial statements were prepared in accordance with the accounting principles generally accepted in the United States of America. Accordingly, we believe that our consolidated financial statements included herein fairly present, in all material respects, our consolidated financial condition, consolidated results of operationsreporting process and cash flows as of and for the reporting periods then ended.


23


Remediation of Material Weaknesses

The Company remediated certain of the material weaknesses in our disclosure controls and procedures identified above by adding independent directors and by hiring a CFO with SEC reporting experience. Effective November 17, 2017, the Board of Directors filled then existing vacancies in the Board by appointing each of the following persons as a member of the Board: William E. Kingsford; Thomas E. Scott, CPA; Paul D. Jones; and Roy M. Harsch, each to serve until the next annual meeting of the shareholders, or until his successor has been duly qualified and appointed. On December 1, 2017, the Board of Directors consisting of Andrew J. Kandalepas, Jay Joshi, M.D., Messrs. Kingsford, Scott, Jones, and Harsch, accepted the voluntary resignation of Mr. Kandalepas, as President, and appointed Mr. Jones as President. Mr. Kandalepas’ resignation and Mr. Jones’ appointment were effective immediately. On February 5, 2018, the Board of Directors appointed Calvin R. O’Harrow as Chief Operating Officer and a member of the Board. It accepted the resignation of Andrew J. Kandalepas as Chief Financial Officer (CFO) and Principal Accounting Officer (PAO) and appointed Douglas W. Samuelson, CPA, as CFO and PAO. It also removed Jay Joshi, M.D., as a Director. The Board of Directors also appointed a Compensation Committee consisting of Messrs. Jones, Scott and Kingsford.

The company has implemented the following corporate policies to remediate the noted material weaknesses:

All Debt agreements must be approved by the Board  

All Equity grants must be approved by the Board  

All Officers must have an agreement approved by the Board  

All employees must have a written agreement  

Consultant agreements with payments totaling over $20,000 must be approved by the Board  

Create a Board compensation plan  

Create an Audit Committee with an Audit Committee Charter  

Create a policy for Board approval on cash disbursements over $20,000  

Create a policy to ensure no one at any entity can initiate a payment to themselves  

Create controls over all Press Releases  

Ensure the Company will only work with licensed dealer/brokers relating to the sale of equity instruments  

Management's Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the issuer’s principal executive and principal financial officer and effected by the issuer’s board of directors, management and other personnel, todid not provide reasonable assurance regarding the reliabilitythat accounts were complete and accurate and agreed to detailed support and that reconciliations of financial reportingaccounts were properly performed, reviewed and the preparation of financial statements for external purposes in accordance with accounting principles generally acceptedapproved.

25

The Company is committed to remediating its material weaknesses as promptly as possible. However, there can be no assurance as to when these material weaknesses will be remediated or that additional material weaknesses will not arise in the United States of America and includes those policies and procedures that:

Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the issuer;  

only in accordance with authorizations of management and directors of the issuer; and Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America and that receipts and expenditures of the Company are being made  

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the issuer’s assets that could have a material effect on the financial statements.  

Because of its inherent limitations,future. Even effective internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statementthe preparation and presentation. Becausefair presentation of financial statements. Any failure to remediate the inherent limitationsmaterial weaknesses, or the development of internal control, there is a risk thatnew material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.


24


As of the end of our most recent fiscal year, management assessed the effectiveness ofweaknesses in our internal control over financial reporting, basedcould result in material misstatements in our financial statements, which in turn could have a material adverse effect on our financial condition and the criteria fortrading price of our common stock and we could fail to meet our financial reporting obligations. We have identified weaknesses in our internal controls, and we cannot provide assurances that these weaknesses will be effectively remediated or that additional material weaknesses will not occur in the future.

If not remediated, our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting establishedcould result in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") and SEC guidance on conducting such assessments. Based on that evaluation, they concluded that, as of September 30, 2017, such internal control over financial reporting was not effective. This was due to deficiencies that existedmaterial misstatements in the design or operation of our internal control over financial reporting that adversely affected our internal controls and that may be considered to be material weaknesses.

The matters involving internal control over financial reporting that our management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were: (1) lack of a functioning audit committee due to a lack of a majority of independent members and a lack of a majority of outside directors on our board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; (2) inadequate segregation of duties consistent with control objectives of having segregation of the initiation of transactions, the recording of transactions and the custody of assets; and (3) ineffective controls over period end financial disclosure and reporting processes. The aforementioned material weaknesses were identified by our Chief Executive Officer in connection with the review of our financial statements asand a failure to meet our reporting and financial obligations, each of September 30, 2017.

To address thewhich could have a material weaknesses set forth in items (2) and (3) discussed above, management performed additional analyses and other procedures to ensure that the financial statements included herein fairly present, in all material respects,adverse effect on our financial position, resultscondition and the trading price of operations and cash flows for the periods presented.our common stock.

This Report does not include an attestation report of the Company's independent registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's independent registered public accounting firm pursuant to the rules of the SEC that permit the Company to provide only the management's report in this Report.

Management's Remediation Initiatives

In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we have initiated, or plan to initiate, all of the series of measures noted above in Remediation of Material Weaknesses.

Changes in internal control over financial reporting.

There have been no changes in our internal control over financial reporting that occurred(as such term is defined in Rules 13a-15(f) and 15d-15 (f) under the Exchange Act) during the quarter covered by this Quarterly Report on Form 10-Qsix months ended March 31, 2022 that hashave materially affected, or isare reasonably likely to materially affect, our internal control over financial reporting.


25


PART II - OTHER INFORMATION

Item 1. Legal Proceedings

The Company is periodically engaged in legal proceedings arising from and relating to its business operations. WeExcept as otherwise described herein, we currently are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our companyCompany or any of our subsidiaries, threatened against or affecting our company,Company, our common stock, any of our subsidiaries or of our companiesCompany’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.effect on our financial condition or results of operations.

In June, 2015,The Company continues efforts to preserve revenue and reduce operating expenses through actions including, but not limited to, facilities consolidation and staff reductions, which it hopes to implement through negotiated transactions with lessors, employees and other third parties. Such actions may result in disputes with and claims by such parties which, if not resolved through negotiations, may impact negatively the Company’s ability to continue as a going concern. To date, the Company has negotiated settlement of all ex-employee wage and its CEO receivedbenefits claims except for the claim filed with the Illinois Department of Labor asserting a formal order of investigation from the Chicago Regional Staffviolation of the SEC.Illinois Wage Payment and Collection Act by the Company’s former CEO. That claim alleges unpaid wages in the amount of $158,715 and unpaid vacation pay in the amount of $20,833 for a total amount of $179,548, as well as certain statutory damages including, but not limited to, 2% of the wages due per month plus attorneys’ fees if the ex-CEO elects to file suit for a violation of the Act and is successful in obtaining a judgment on his claim. The Company has filed its response to such claim with the Department denying the substantive allegations therein and its CEO cooperatedasserting certain factual and delivered requested documents, testimony, and tolling agreements.

In May, 2017,legal defenses, including breach of fiduciary duty, as a bar to all claimed compensation. The claim remains pending, but as the Staff issued a Wells Notice stating its preliminary determination to recommend an enforcement actiondate hereof, no suit has been filed against the Company and its CEOasserting a violation of the Act based on possible violationssaid claim.

As discussed in Note 5, on or about June 29, 2020, HHE filed case number 2020L006092 in the Circuit Court of Section 17(a)Cook County alleging failure to pay Base Rent and abandonment of certain office space in Hoffman Estates, Illinois subject to a Commercial Lease dated May 26, 2016 (the “HHE litigation”). HHE sought at least $672,888 in base rent and other amounts under the lease, as well as treble damages from our ex-CEO and two past Directors who were serving on our Board as of the Securities Act, Sections 15 (a) and 10(b)date of the Exchange Act,lease. On October 6, 2021, HHE and Rule 10b-5 thereunder. The Staff would allege, among other things, that periodic reports issued during 2013 and 2014 were misleading because they failedthe Company agreed to disclosea settlement on the terms discussed in Note 5 above. On February 10, 2022, the initial payment of $125,000 was paid to HHE (see Note 5).

26

On or mischaracterizedabout January 8, 2021, Periklis Papadopoulus, a former Director who was named as “salary”, “prepayments” or “loans,” several payments totaling $450,000 made to our CEO during those years without prior Board approval; that two press releases issuedan additional Defendant in 2015 touted shipments of several Psoria-Light devices that were not closed sales; and that we used an unregistered broker-dealer to identify and solicit potential investors during 2013, 2015 and 2017.

Subsequent discussions resulted in our submission of an Offer of Settlement (“Offer”) through an administrative cease and desist action on November 17, 2017. Pursuant to the Offer, we neither admit nor deny any of the proposed allegations, but are enjoined from violating the above-referenced Sections and Rule. The Offer imposes no financial penalties or sanctionsHHE litigation, filed a counterclaim against the Company seeking indemnification for attorneys’ fees he incurred in obtaining his dismissal from the HHE litigation. Subsequent to September 30, 2021, the Company settled the counterclaim by agreeing to pay $41,914, with $15,000 payable on or about January 4, 2022 and is subject to final SEC approval. The CEO did not jointhe balance in sixteen monthly installments commencing June 4, 2022, each in the Offeramount of $1,791. The settlement amount shall be reduced to $37,000 if it is paid prior to April 1, 2022, or $39,000 if paid before July 1, 2022. The Company agreed to entry of a judgment in the amount of $41,914 to secure payments under the settlement agreement. Upon payment of the settlement, Papadopoulos will provide the Company with a satisfaction of judgment. During the three months ended March 31, 2022, but prior to April 1, 20122, the Company made payments totaling $37,000. This satisfied the judgment as of March 31, 2022 and may contest any action that may be asserted against him.the Company recorded a gain on settlement of debt of $4,914 during the three months ended March 31, 2022.

Item 1A. Risk Factors

Not required for smaller reporting companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None

Item 6. Exhibits

Exhibit No.

Description

31.1

31.2

Certification of Principal Executive Officer Pursuant to Rule 13a-14*

31.2Certification of Principal Financial Officer Pursuant to Rule 13a-14*

32.1

32.2

CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act*

32.2CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act*

101.INS

Inline XBRL Instance Document**

101.SCH

Inline XBRL Taxonomy Extension Schema**

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase**

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase**

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase**

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase**

104Cover Page Interactive Data File (embedded within the Inline XBRL document)

26


* Filed herewith.

**Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability.


27


SIGNATURES

27

 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, there unto duly authorized.

WELLNESS CENTER USA, INC.

Date: February 27, 2018

May 23, 2022

By:

/s/ Paul D. Jones

Paul D. Jones

President

(Duly Authorized Principal Executive Officer)

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, there unto duly authorized.

WELLNESS CENTER USA, INC.

Date: February 27, 2018

May 23, 2022

By:

/s/ Douglas W. Samuelson

Douglas W. Samuelson

Chief Financial Officer and Principal Accounting Officer

(Duly Authorized Principal Accounting Officer)


28


POWER OF ATTORNEY

Each person whose signature appears below hereby constitutes and appoints severally Paul D. Jones, his true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SIGNATURE

TITLE

DATE

SIGNATURE

TITLE

DATE

/s/ Andrew J. KandalepasCalvin O’Harrow

Chairman, Chief Executive Officer,

Director

February 27, 2018

May 23, 2022

Andrew J. Kandalepas

Calvin O’Harrow

/s/ Douglas W. Samuelson

Chief Financial Officer and Principal Accounting Officer

February 27, 2018

May 23, 2022

Douglas W. Samuelson

/s/ Paul D. Jones

Director, President

February 27, 2018

May 23, 2022

Paul D. Jones

/s/ Thomas E. Scott

Director, Secretary

February 27, 2018

May 23, 2022

Thomas E. Scott

Thomas E. Scott

/s/ William E. Kingsford

Director

February 27, 2018

May 23, 2022

William E. Kingsford

William E. Kingsford

/s/ Roy M. Harsch

Director,

Chairman

February 27, 2018

May 23, 2022
Roy M. Harsch

Roy M. Harsch

/s/ Calvin R. O’Harrow

Director, Chief Operating Officer

February 27, 2018

28

Calvin R. O’Harrow


29